194 results on '"Gunter M.J."'
Search Results
2. Coffee consumption is associated with a reduced risk of colorectal cancer recurrence and all-cause mortality.
- Author
-
Oyelere, A.M., Kok, D.E., Bos, D., Gunter, M.J., Ferrari, Pietro, Keski-Rahkonen, P., Wilt, J.H.W. de, Halteren, H.K. van, Kouwenhoven, E.A., Duijnhoven, F. J. B. van, Kampman, E., Oyelere, A.M., Kok, D.E., Bos, D., Gunter, M.J., Ferrari, Pietro, Keski-Rahkonen, P., Wilt, J.H.W. de, Halteren, H.K. van, Kouwenhoven, E.A., Duijnhoven, F. J. B. van, and Kampman, E.
- Abstract
Contains fulltext : 306358.pdf (Publisher’s version ) (Open Access), Coffee consumption has been associated with a reduced risk of developing colorectal cancer (CRC). However, it is not clear whether coffee consumption is related to CRC progression. Hence, we assessed the association of coffee consumption with CRC recurrence and all-cause mortality using data from a prospective cohort study of 1719 stage I-III CRC patients in the Netherlands. Coffee consumption and other lifestyle characteristics were self-reported using questionnaires at the time of diagnosis. We retrieved recurrence and all-cause mortality data from the Netherlands Cancer Registry and the Personal Records Database, respectively. Cox proportional hazard regression models with and without restricted cubic splines were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) adjusted for age, sex, education, smoking status, cancer stage and tumor location. We observed 257 recurrences during a 6.2-year median follow-up and 309 deaths during a 6.6-year median follow-up. Consuming more than 4 cups/d of coffee compared to an intake of <2 cups/d was associated with a 32% lower risk of CRC recurrence (95% CI: 0.49, 0.94,). The association between coffee consumption and all-cause mortality was U-shaped; coffee intake seemed optimal at 3-5 cups/d with the lowest risk at 4 cups/d (HR: 0.68, 95% CI: 0.53, 0.88). Our results suggest that coffee consumption may be associated with a lower risk of CRC recurrence and all-cause mortality. The association between coffee consumption and all-cause mortality appeared nonlinear. More studies are needed to understand the mechanism by which coffee consumption might improve CRC prognosis.
- Published
- 2024
3. Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis
- Author
-
Yarmolinsky, J., Robinson, J.W., Mariosa, D., Karhunen, V., Huang, Jian, Dimou, N., Murphy, N., Burrows, K., Bouras, E., Smith-Byrne, K., Lewis, S.J., Galesloot, T.E., Kiemeney, B., Vermeulen, S., Martin, P., Albanes, D., Hou, L., Newcomb, P.A., White, E., Wolk, A., Wu, A.H., Marchand, L. Le, Phipps, A.I., Buchanan, D.D., Zhao, S.S., Gill, D., Chanock, S.J., Purdue, M.P., Smith, G. Davey, Brennan, P., Herzig, K.H., Järvelin, M.R., Amos, C.I., Hung, R.J., Dehghan, A., Johansson, M., Gunter, M.J., Tsilidis, K.K., Martin, R.M., Yarmolinsky, J., Robinson, J.W., Mariosa, D., Karhunen, V., Huang, Jian, Dimou, N., Murphy, N., Burrows, K., Bouras, E., Smith-Byrne, K., Lewis, S.J., Galesloot, T.E., Kiemeney, B., Vermeulen, S., Martin, P., Albanes, D., Hou, L., Newcomb, P.A., White, E., Wolk, A., Wu, A.H., Marchand, L. Le, Phipps, A.I., Buchanan, D.D., Zhao, S.S., Gill, D., Chanock, S.J., Purdue, M.P., Smith, G. Davey, Brennan, P., Herzig, K.H., Järvelin, M.R., Amos, C.I., Hung, R.J., Dehghan, A., Johansson, M., Gunter, M.J., Tsilidis, K.K., and Martin, R.M.
- Abstract
Contains fulltext : 304872.pdf (Publisher’s version ) (Open Access), BACKGROUND: Tumour-promoting inflammation is a "hallmark" of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear. METHODS: We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry. We then used combined cis-Mendelian randomization and colocalisation analysis to evaluate the causal role of 66 circulating inflammatory markers in risk of 30 adult cancers in 338,294 cancer cases and up to 1,238,345 controls. Genetic instruments for inflammatory markers were constructed using genome-wide significant (P < 5.0 × 10(-8)) cis-acting SNPs (i.e., in or ±250 kb from the gene encoding the relevant protein) in weak linkage disequilibrium (LD, r(2) < 0.10). Effect estimates were generated using inverse-variance weighted random-effects models and standard errors were inflated to account for weak LD between variants with reference to the 1000 Genomes Phase 3 CEU panel. A false discovery rate (FDR)-corrected P-value ("q-value") <0.05 was used as a threshold to define "strong evidence" to support associations and 0.05 ≤ q-value < 0.20 to define "suggestive evidence". A colocalisation posterior probability (PPH(4)) >70% was employed to indicate support for shared causal variants across inflammatory markers and cancer outcomes. Findings were replicated in the FinnGen study and then pooled using meta-analysis. FINDINGS: We found strong evidence to support an association of genetically-proxied circulating pro-adrenomedullin concentrations with increased breast cancer risk (OR: 1.19, 95% CI: 1.10-1.29, q-value = 0.033, PPH(4) = 84.3%) and suggestive evidence to support associations of interleukin-23 receptor concentrations with increased pancreatic cancer risk (OR: 1.42, 95% CI: 1.20-1.69, q-value = 0
- Published
- 2024
4. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women
- Author
-
Murphy, N., Knuppel, A., Papadimitriou, N., Martin, R.M., Tsilidis, K.K., Smith-Byrne, K., Fensom, G., Perez-Cornago, A., Travis, R.C., Key, T.J., and Gunter, M.J.
- Published
- 2020
- Full Text
- View/download PDF
5. Identification of a dietary pattern related to gut microbial diversity and its association with metabolic health status in Korean adults
- Author
-
Noh, H., primary, Jang, H.-H., additional, Fervers, B., additional, Keski-Rahkonen, P., additional, Freisling, H., additional, and Gunter, M.J., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Reproducibility of 35 plasma polyphenol concentrations and their association with colon cancer risk in a japanese middle-aged population
- Author
-
Mori, N., primary, Murphy, N., additional, Sawada, N., additional, Achaintre, D., additional, Yamaji, T., additional, Scalbert, A., additional, Ishihara, J., additional, Takachi, R., additional, Nakamura, K., additional, Tanaka, J., additional, Iwasaki, M., additional, Iso, H., additional, Inoue, M., additional, Gunter, M.J., additional, and Tsugane, S., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Meeting report from the joint IARC–NCI international cancer seminar series: a focus on colorectal cancer
- Author
-
Gunter, M.J., Alhomoud, S., Arnold, M., Brenner, H., Burn, J., Casey, G., Chan, A.T., Cross, A.J., Giovannucci, E., Hoover, R., Houlston, R., Jenkins, M., Laurent-Puig, P., Peters, U., Ransohoff, D., Riboli, E., Sinha, R., Stadler, Z.K., Brennan, P., and Chanock, S.J.
- Published
- 2019
- Full Text
- View/download PDF
8. A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study
- Author
-
Chajès, V., Assi, N., Biessy, C., Ferrari, P., Rinaldi, S., Slimani, N., Lenoir, G.M., Baglietto, L., His, M., Boutron-Ruault, M.C., Trichopoulou, A., Lagiou, P., Katsoulis, M., Kaaks, R., Kühn, T., Panico, S., Pala, V., Masala, G., Bueno-de-Mesquita, H.B., Peeters, P.H., van Gils, C., Hjartåker, A., Standahl Olsen, K., Borgund Barnung, R., Barricarte, A., Redondo-Sanchez, D., Menéndez, V., Amiano, P., Wennberg, M., Key, T., Khaw, K.T., Merritt, M.A., Riboli, E., Gunter, M.J., and Romieu, I.
- Published
- 2017
- Full Text
- View/download PDF
9. Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)
- Author
-
Nitter, M., Norgård, B., de Vogel, S., Eussen, S.J.P.M., Meyer, K., Ulvik, A., Ueland, P.M., Nygård, O., Vollset, S.E., Bjørge, T., Tjønneland, A., Hansen, L., Boutron-Ruault, M., Racine, A., Cottet, V., Kaaks, R., Kühn, T., Trichopoulou, A., Bamia, C., Naska, A., Grioni, S., Palli, D., Panico, S., Tumino, R., Vineis, P., Bueno-de-Mesquita, H.B., van Kranen, H., Peeters, P.H., Weiderpass, E., Dorronsoro, M., Jakszyn, P., Sánchez, M., Argüelles, M., Huerta, J.M., Barricarte, A., Johansson, M., Ljuslinder, I., Khaw, K., Wareham, N., Freisling, H., Duarte-Salles, T., Stepien, M., Gunter, M.J., and Riboli, E.
- Published
- 2014
- Full Text
- View/download PDF
10. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort
- Author
-
Tikk, K., Sookthai, D., Johnson, T., Rinaldi, S., Romieu, I., Tjønneland, A., Olsen, A., Overvad, K., Clavel-Chapelon, F., Baglietto, L., Boeing, H., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Pala, V., Tumino, R., Rosso, S., Panico, S., Agudo, A., Menéndez, V., Sánchez, M.-J., Amiano, P., Huerta Castaño, J.M., Ardanaz, E., Bueno-de-Mesquita, H.B., Monninkhof, E., Onland-Moret, C., Andersson, A., Sund, M., Weiderpass, E., Khaw, K.-T., Key, T.J., Travis, R.C., Gunter, M.J., Riboli, E., Dossus, L., and Kaaks, R.
- Published
- 2014
- Full Text
- View/download PDF
11. Plasma concentrations and intakes of amino acids in male meat-eaters, fish-eaters, vegetarians and vegans: a cross-sectional analysis in the EPIC-Oxford cohort
- Author
-
Schmidt, J.A., Rinaldi, S., Scalbert, A., Ferrari, P., Achaintre, D., Gunter, M.J., Appleby, P.N., Key, T.J., and Travis, R.C.
- Subjects
Amino acids -- Health aspects -- Comparative analysis ,Blood plasma -- Health aspects -- Comparative analysis ,Food/cooking/nutrition ,Health - Abstract
BACKGROUND/OBJECTIVES: We aimed to investigate the differences in plasma concentrations and in intakes of amino acids between male meat-eaters, fish-eaters, vegetarians and vegans in the Oxford arm of the European Prospective Investigation into Cancer and Nutrition. SUBJECTS/METHODS: This cross-sectional analysis included 392 men, aged 30-49 years. Plasma amino acid concentrations were measured with a targeted metabolomic approach using mass spectrometry, and dietary intake was assessed using a food frequency questionnaire. Differences between diet groups in mean plasma concentrations and intakes of amino acids were examined using analysis of variance, controlling for potential confounding factors and multiple testing. RESULTS: In plasma, concentrations of 6 out of 21 amino acids varied significantly by diet group, with differences of -13% to +16% between meat-eaters and vegans. Concentrations of methionine, tryptophan and tyrosine were highest in fish-eaters and vegetarians, followed by meat-eaters, and lowest in vegans. A broadly similar pattern was seen for lysine, whereas alanine concentration was highest in fish-eaters and lowest in meat-eaters. For glycine, vegans had the highest concentration and meat-eaters the lowest. Intakes of all 18 dietary amino acids differed by diet group;for the majority of these, intake was highest in meat-eaters followed by fish-eaters, then vegetarians and lowest in vegans (up to 47% lower than in meat-eaters). CONCLUSIONS: Men belonging to different habitual diet groups have significantly different plasma concentrations of lysine, methionine, tryptophan, alanine, glycine and tyrosine. However, the differences in plasma concentrations were less marked than and did not necessarily mirror those seen for amino acid intakes. European Journal of Clinical Nutrition (2016) 70, 306-312; doi:10.1038/ejcn.2015.144; published online 23 September 2015, INTRODUCTION Amino acids are the building blocks of proteins (1) and are additionally utilised as a source of energy. They are necessary for the synthesis of a wide variety of [...]
- Published
- 2016
- Full Text
- View/download PDF
12. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk
- Author
-
Porta, Miquel, Gasull, M., Pumarega, J., Kiviranta, Hannu, Rantakokko, Panu, Raaschou-Nielsen, Ole, Bergdahl, Ingvar A, Sandanger, Torkjel Manning, Agudo, Antonio, Rylander, Charlotta, Nøst, Therese Haugdahl, Aune, Dagfinn, Heath, A.K., Cirera, Lluis, Goñi-Irigoyen, Fernando, Alguacil, Juan, Gimenez-Robert, Alex, Tjonneland, Anne, Sund, Malin, Overvad, Kim, Mancini, Francesca Romana, Rebours, V., Boutron-Ruault, Marie Christine, Kaaks, Rudolf, Schulze, M.B., Trichopoulou, Antonia, Palli, Domenico, Grioni, Sara, Tumino, Rosario, Naccarati, Alessio, Panico, Salvatore, Vermeulen, Roel, Quiros, J.R., Rodriguez-Barranco, Miguel, Colorado-Yohar, Sandra, Chirlaque, Maria Dolores, Ardanaz, Eva, Wareham, Nick J, Key, Timothy, Johansson, Mattias, Murphy, Neil, Ferrari, Pietro, Huybrechts, Inge, Chajes, V., González, Carlos A., Bas Bueno-de-Mesquita, Bas Bueno-de-Mesquita, Gunter, M.J., Weiderpass, Elisabete, Riboli, Elio, Duell, Eric J., Katzke, Verena, Vineis, Paolo, and IRAS OH Epidemiology Chemical Agents
- Subjects
biomarkers ,environmental health ,Pancreatic cancer ,persistent organic pollutants ,methods - Abstract
Background: Findings and limitations of previous studies on persistent organic pollutants (POPs) and pancreatic cancer risk support conducting further research in prospective cohorts. Methods: We conducted a prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Participants were 513 pancreatic cancer cases and 1020 matched controls. Concentrations of 22 POPs were measured in plasma collected at baseline. Results: Some associations were observed at higher concentrations of p, p'-DDT, trans-nonachlor, β-hexachlorocyclohexane and the sum of six organochlorine pesticides and of 16 POPs. The odds ratio (OR) for the upper quartile of trans-nonachlor was 1.55 (95% confidence interval 1.06-2.26; P for trend = 0.025). Associations were stronger in the groups predefined as most valid (participants having fasted >6 h, with microscopic diagnostic confirmation, normal weight, and never smokers), and as most relevant (follow-up ≥10 years). Among participants having fasted >6 h, the ORs were relevant for 10 of 11 exposures. Higher ORs were also observed among cases with microscopic confirmation than in cases with a clinical diagnosis, and among normal-weight participants than in the rest of participants. Among participants with a follow-up ≥10 years, estimates were higher than in participants with a shorter follow-up (for trans-nonachlor: OR = 2.14, 1.01 to 4.53, P for trend = 0.035). Overall, trans-nonachlor, three PCBs and the two sums of POPs were the exposures most clearly associated with pancreatic cancer risk. Conclusions: Individually or in combination, most of the 22 POPs analysed did not or only moderately increased the risk of pancreatic cancer.
- Published
- 2022
13. Pre-diagnostic C-reactive protein concentrations, CRP genetic variation and mortality among individuals with colorectal cancer in Western European populations
- Author
-
Nimptsch, K., Aleksandrova, K., Fedirko, V., Jenab, M., Gunter, M.J., Siersema, P.D., Wu, K., Katzke, V., Kaaks, R., Panico, S., Palli, D., May, A.M., Sieri, S., Bueno-de-Mesquita, B., Standahl, K., Sánchez, M.J., Perez-Cornago, A., Olsen, A., Tjønneland, A., Bonet, C.B., Dahm, C.C., Chirlaque, M.D., Fiano, V., Tumino, R., Gurrea, A.B., Boutron-Ruault, M.C., Menegaux, F., Severi, G., Guelpen, B. van, Lee, Y.A., Pischon, T., Nimptsch, K., Aleksandrova, K., Fedirko, V., Jenab, M., Gunter, M.J., Siersema, P.D., Wu, K., Katzke, V., Kaaks, R., Panico, S., Palli, D., May, A.M., Sieri, S., Bueno-de-Mesquita, B., Standahl, K., Sánchez, M.J., Perez-Cornago, A., Olsen, A., Tjønneland, A., Bonet, C.B., Dahm, C.C., Chirlaque, M.D., Fiano, V., Tumino, R., Gurrea, A.B., Boutron-Ruault, M.C., Menegaux, F., Severi, G., Guelpen, B. van, Lee, Y.A., and Pischon, T.
- Abstract
Contains fulltext : 252185.pdf (Publisher’s version ) (Open Access), BACKGROUND: The role of elevated pre-diagnostic C-reactive protein (CRP) concentrations on mortality in individuals with colorectal cancer (CRC) remains unclear. METHODS: We investigated the association between pre-diagnostic high-sensitivity CRP concentrations and CRP genetic variation associated with circulating CRP and CRC-specific and all-cause mortality based on data from 1,235 individuals with CRC within the European Prospective Investigation into Cancer and Nutrition cohort using multivariable-adjusted Cox proportional hazards regression. RESULTS: During a median follow-up of 9.3 years, 455 CRC-specific deaths were recorded, out of 590 deaths from all causes. Pre-diagnostic CRP concentrations were not associated with CRC-specific (hazard ratio, HR highest versus lowest quintile 0.92, 95% confidence interval, CI 0.66, 1.28) or all-cause mortality (HR 0.91, 95% CI 0.68, 1.21). Genetic predisposition to higher CRP (weighted score based on alleles of four CRP SNPs associated with higher circulating CRP) was not significantly associated with CRC-specific mortality (HR per CRP-score unit 0.95, 95% CI 0.86, 1.05) or all-cause mortality (HR 0.98, 95% CI 0.90, 1.07). Among four investigated CRP genetic variants, only SNP rs1205 was significantly associated with CRC-specific (comparing the CT and CC genotypes with TT genotype, HR 0.54, 95% CI 0.35, 0.83 and HR 0.58, 95% CI 0.38, 0.88, respectively) and all-cause mortality (HR 0.58, 95% CI 0.40, 0.85 and 0.64, 95% CI 0.44, 0.92, respectively). CONCLUSIONS: The results of this prospective cohort study do not support a role of pre-diagnostic CRP concentrations on mortality in individuals with CRC. The observed associations with rs1205 deserve further scientific attention.
- Published
- 2022
14. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk
- Author
-
IRAS OH Epidemiology Chemical Agents, Porta, Miquel, Gasull, M., Pumarega, J., Kiviranta, Hannu, Rantakokko, Panu, Raaschou-Nielsen, Ole, Bergdahl, Ingvar A, Sandanger, Torkjel Manning, Agudo, Antonio, Rylander, Charlotta, Nøst, Therese Haugdahl, Aune, Dagfinn, Heath, A.K., Cirera, Lluis, Goñi-Irigoyen, Fernando, Alguacil, Juan, Gimenez-Robert, Alex, Tjonneland, Anne, Sund, Malin, Overvad, Kim, Mancini, Francesca Romana, Rebours, V., Boutron-Ruault, Marie Christine, Kaaks, Rudolf, Schulze, M.B., Trichopoulou, Antonia, Palli, Domenico, Grioni, Sara, Tumino, Rosario, Naccarati, Alessio, Panico, Salvatore, Vermeulen, Roel, Quiros, J.R., Rodriguez-Barranco, Miguel, Colorado-Yohar, Sandra, Chirlaque, Maria Dolores, Ardanaz, Eva, Wareham, Nick J, Key, Timothy, Johansson, Mattias, Murphy, Neil, Ferrari, Pietro, Huybrechts, Inge, Chajes, V., González, Carlos A., Bas Bueno-de-Mesquita, Bas Bueno-de-Mesquita, Gunter, M.J., Weiderpass, Elisabete, Riboli, Elio, Duell, Eric J., Katzke, Verena, Vineis, Paolo, IRAS OH Epidemiology Chemical Agents, Porta, Miquel, Gasull, M., Pumarega, J., Kiviranta, Hannu, Rantakokko, Panu, Raaschou-Nielsen, Ole, Bergdahl, Ingvar A, Sandanger, Torkjel Manning, Agudo, Antonio, Rylander, Charlotta, Nøst, Therese Haugdahl, Aune, Dagfinn, Heath, A.K., Cirera, Lluis, Goñi-Irigoyen, Fernando, Alguacil, Juan, Gimenez-Robert, Alex, Tjonneland, Anne, Sund, Malin, Overvad, Kim, Mancini, Francesca Romana, Rebours, V., Boutron-Ruault, Marie Christine, Kaaks, Rudolf, Schulze, M.B., Trichopoulou, Antonia, Palli, Domenico, Grioni, Sara, Tumino, Rosario, Naccarati, Alessio, Panico, Salvatore, Vermeulen, Roel, Quiros, J.R., Rodriguez-Barranco, Miguel, Colorado-Yohar, Sandra, Chirlaque, Maria Dolores, Ardanaz, Eva, Wareham, Nick J, Key, Timothy, Johansson, Mattias, Murphy, Neil, Ferrari, Pietro, Huybrechts, Inge, Chajes, V., González, Carlos A., Bas Bueno-de-Mesquita, Bas Bueno-de-Mesquita, Gunter, M.J., Weiderpass, Elisabete, Riboli, Elio, Duell, Eric J., Katzke, Verena, and Vineis, Paolo
- Published
- 2022
15. Obesity is Associated With Increased Risk of Crohn's disease, but not Ulcerative Colitis: A Pooled Analysis of Five Prospective Cohort Studies
- Author
-
IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Casey, K., Olen, O., Ludvigsson, J.F., Carbonnel, F., Oldenburg, B., Gunter, M.J., Tjønneland, A., Grip, O., Amian, P., Barricarte, A., Bergmann, M.M., Boutron-Ruault, M.-C., Cross, A., Hart, A.R., Kaaks, R., Key, T., Chirlaque López, M.D., Luben, Robert, Masala, G., Manjer, J., Olsen, A., Overvad, K., Palli, D., Riboli, E., Sánchez, M.J., Tumino, R., Vermeulen, R., Verschuren, W.M.M., Wareham, N., Ananthakrishnan, A., Burke, K., Lopes, E.W., Lochhead, P., Chan, A.T., Wolk, A., Khalili, H., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Casey, K., Olen, O., Ludvigsson, J.F., Carbonnel, F., Oldenburg, B., Gunter, M.J., Tjønneland, A., Grip, O., Amian, P., Barricarte, A., Bergmann, M.M., Boutron-Ruault, M.-C., Cross, A., Hart, A.R., Kaaks, R., Key, T., Chirlaque López, M.D., Luben, Robert, Masala, G., Manjer, J., Olsen, A., Overvad, K., Palli, D., Riboli, E., Sánchez, M.J., Tumino, R., Vermeulen, R., Verschuren, W.M.M., Wareham, N., Ananthakrishnan, A., Burke, K., Lopes, E.W., Lochhead, P., Chan, A.T., Wolk, A., and Khalili, H.
- Published
- 2022
16. Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort
- Author
-
Matejcic, M., de Batlle, J., Ricci, C., Biessy, C., Perrier, F., Huybrechts, I., Weiderpass, E., BoutronRuault, M.C., Cadeau, C., His, M., Cox, D.G., Boeing, H., Fortner, R.T., Kaaks, R., Lagiou, P., Trichopoulou, A., Benetou, V., Tumino, R., Panico, S., Sieri, S., Palli, D., Ricceri, F., BuenodeMesquita, H.B(as), Skeie, G., Amiano, P., Sánchez, M.J., Chirlaque, M.D., Barricarte, A., Quirós, J.R., Buckland, G., van Gils, C.H., Peeters, P.H., Key, T.J., Riboli, E., Gylling, B., ZeleniuchJacquotte, A., Gunter, M.J., Romieu, I., and Chajès, V.
- Published
- 2017
- Full Text
- View/download PDF
17. A new pipeline for the normalization and pooling of metabolomics data
- Author
-
Viallon, V., His, M., Rinaldi, S., Breeur, M., Gicquiau, A., Hemon, B., Overvad, K., Tjønneland, A., Rostgaard-Hansen, A.L., Rothwell, J.A., Lecuyer, L., Severi, G., Kaaks, R., Johnson, T., Schulze, M.B., Palli, D., Agnoli, C., Panico, S., Tumino, R., Ricceri, F., Monique Verschuren, W.M., Engelfriet, P., Onland-Moret, C., Vermeulen, R., Nøst, T.H., Urbarova, I., Zamora-Ros, R., Rodriguez-Barranco, M., Amiano, P., Huerta, J.M., Ardanaz, E., Melander, O., Ottoson, F., Vidman, L., Rentoft, M., Schmidt, J.A., Travis, R.C., Weiderpass, E., Johansson, M., Dossus, L., Jenab, M., Gunter, M.J., Bermejo, J.L., Scherer, D., Salek, R.M., Keski-Rahkonen, P., Ferrari, P., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, and Sub Inorganic Chemistry and Catalysis
- Subjects
Normalization (statistics) ,Pooling ,Computer science ,Pipeline (computing) ,Endocrinology, Diabetes and Metabolism ,computer.software_genre ,Microbiology ,Biochemistry ,Generalized linear mixed model ,Statistical power ,Article ,03 medical and health sciences ,Endocrinology ,0302 clinical medicine ,Cancer epidemiology ,Metabolites ,Metabolomics ,Imputation (statistics) ,Càncer ,Molecular Biology ,030304 developmental biology ,Cancer ,0303 health sciences ,Cancer och onkologi ,Bioinformatics (Computational Biology) ,Normalization ,Technical variability ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,Missing data ,QR1-502 ,3. Good health ,Diabetes and Metabolism ,Metabolòmica ,030220 oncology & carcinogenesis ,Cancer and Oncology ,Outlier ,Bioinformatik (beräkningsbiologi) ,Data mining ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,computer - Abstract
Pooling metabolomics data across studies is often desirable to increase the statistical power of the analysis. However, this can raise methodological challenges as several preanalytical and analytical factors could introduce differences in measured concentrations and variability between datasets. Specifically, different studies may use variable sample types (e.g., serum versus plasma) collected, treated, and stored according to different protocols, and assayed in different laboratories using different instruments. To address these issues, a new pipeline was developed to normalize and pool metabolomics data through a set of sequential steps: (i) exclusions of the least informative observations and metabolites and removal of outliers, imputation of missing data, (ii) identification of the main sources of variability through principal component partial R-square (PC-PR2) analysis, (iii) application of linear mixed models to remove unwanted variability, including samples’ originating study and batch, and preserve biological variations while accounting for potential differences in the residual variances across studies. This pipeline was applied to targeted metabolomics data acquired using Biocrates AbsoluteIDQ kits in eight case-control studies nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Comprehensive examination of metabolomics measurements indicated that the pipeline improved the comparability of data across the studies. Our pipeline can be adapted to normalize other molecular data, including biomarkers as well as proteomics data, and could be used for pooling molecular datasets, for example in international consortia, to limit biases introduced by inter-study variability. This versatility of the pipeline makes our work of potential interest to molecular epidemiologists.
- Published
- 2021
18. Associations between dietary amino acid intakes and blood concentration levels
- Author
-
Iguacel, I., Perez-Cornago, A., Van Puyvelde, H., Travis, R., Stepien, M., Scalbert, A., Casagrande, C., Weiderpass, E., Riboli, E., Schulze, M.B., Skeie, G., Bodén, S., Boeing, H., Cross, A.J., Harlid, S., Jensen, T.E., Huerta, J.M., Katzke, V., Kühn, T., Lujan-Barroso, L., Masala, G., Rodriguez-Barranco, M., Rostgaard-Hansen, A.L., van der Schouw, Y.T., Vermeulen, R., Tagliabue, G., Tjønneland, A., Trevisan, M., Ferrari, P., Gunter, M.J., Huybrechts, I., IRAS OH Epidemiology Chemical Agents, and dIRAS RA-2
- Subjects
Dietary questionnaire ,Nutrition and Dietetics ,Blood levels ,Dietary intake ,Amino acids ,Critical Care and Intensive Care Medicine ,24-H dietary recall - Abstract
Background and aims: Emerging evidence suggests a role of amino acids (AAs) in the development of various diseases including renal failure, liver cirrhosis, diabetes and cancer. However, mechanistic pathways and the effects of dietary AA intakes on circulating levels and disease outcomes are unclear. We aimed to compare protein and AA intakes, with their respective blood concentrations in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Methods: Dietary protein and AA intakes were assessed via the EPIC dietary questionnaires (DQ) and 24-h dietary recalls (24-HDR). A subsample of 3768 EPIC participants who were free of cancer had blood AA concentrations measured. To investigate how circulating levels relate to their respective intakes, dietary AA intake was examined in quintiles and ANOVA tests were run. Pearson correlations were examined for continous associations between intakes and blood concentrations. Results: Dietary AA intakes (assessed with the DQ) and blood AA concentrations were not strongly correlated (−0.15 ≤ r ≤ 0.17) and the direction of the correlations depended on AA class: weak positive correlations were found for most essential AAs (isoleucine, leucine, lysine, methionine, threonine, tryptophan, and valine) and conditionally essential AAs (arginine and tyrosine), while negative associations were found for non-essential AAs. Similar results were found when using the 24-HDR. When conducting ANOVA tests for essential AAs, higher intake quintiles were linked to higher blood AA concentrations, except for histidine and phenylalanine. For non-essential AAs and glycine, an inverse relationship was observed. Conditionally-essential AAs showed mixed results. Conclusions: Weak positive correlations and dose responses were found between most essential and conditionally essential AA intakes, and blood concentrations, but not for the non-essential AAs. These results suggest that intake of dietary AA might be related to physiological AA status, particularly for the essential AAs. However, these results should be further evaluated and confirmed in large-scale prospective studies.
- Published
- 2021
19. Diabetes and onset of natural menopause: results from the European Prospective Investigation into Cancer and Nutrition
- Author
-
Brand, J.S., Onland-Moret, N.C., Eijkemans, M.J.C., Tjønneland, A., Roswall, N., Overvad, K., Fagherazzi, G., Clavel-Chapelon, F., Dossus, L., Lukanova, A., Grote, V., Bergmann, M.M., Boeing, H., Trichopoulou, A., Tzivoglou, M., Trichopoulos, D., Grioni, S., Mattiello, A., Masala, G., Tumino, R., Vineis, P., Bueno-de-Mesquita, H.B., Weiderpass, E., Redondo, M.L., Sánchez, M.J., Castaño, J.M. Huerta, Arriola, L., Ardanaz, E., Duell, E.J., Rolandsson, O., Franks, P.W., Butt, S., Nilsson, P., Khaw, K.T., Wareham, N., Travis, R., Romieu, I., Gunter, M.J., Riboli, E., and van der Schouw, Y.T.
- Published
- 2015
- Full Text
- View/download PDF
20. Red blood cell fatty acids and risk of colorectal cancer in the European Prospective investigation into cancer and nutrition (EPIC)
- Author
-
Linseisen, J., Grundmann, N., Zoller, D., Kuhn, T., Chajes, V., Fedirko, V., Weiderpass, E., Dahm, C.C., Overvad, K., Tjønneland, A., Boutron-Ruault, M.-C., Rothwell, J.A., Severi, G., Kaaks, R., Schulze, M.B., Aleksandrova, K., Sieri, S., Panico, S., Tumino, R., Masala, G., de Marco, L., Bueno-De-Mesquita, B., Vermeulen, R., Gram, I.T., Skeie, G., Chirlaque, M.-D., Ardanaz, E., Agudo, A., Sánchez, M.-J., Amiano, P., Wennberg, M., Bodén, S., Perez-Cornago, A., Aglago, E.K., Gunter, M.J., Jenab, M., Heath, A.K., Nieters, A., IRAS OH Epidemiology Chemical Agents, and dIRAS RA-2
- Subjects
Oncology ,Epidemiology - Abstract
Background: A growing body of evidence suggests that alterations of dietary fatty acid (FA) profiles are associated with colorectal cancer risk. However, data from large-scale epidemiologic studies using circulating FA measurements to objectively assess individual FA and FA categories are scarce. Methods: We investigate the association between red blood cell (RBC) membrane FAs and risk of colorectal cancer in a case–control study nested within a large prospective cohort. After a median follow-up of 6.4 years, 1,069 incident colorectal cancer cases were identified and matched to 1,069 controls among participants of the European Prospective Investigation into Cancer and Nutrition (EPIC). The FA composition of RBC phospholipids (in mol%) was analyzed by gas chromatography, and their association with risk of colorectal cancer was estimated by multivariable adjusted conditional logistic regression models. Results: After correction for multiple testing, subjects with higher concentrations of RBC stearic acid were at higher risk for colorectal cancer (OR ¼ 1.23; 95% CI ¼ 1.07–1.42, per 1 mol%). Conversely, colorectal cancer incidence decreased with increasing proportions of RBC n-3 PUFA, particularly eicosapentaenoic acid (0.75; 0.62–0.92, per 1 mol%). The findings for the n-6 PUFA arachidonic acid were inconsistent. Conclusions: The positive association between prediagnostic RBC stearic acid and colorectal cancer reflects putative differences in FA intake and metabolism between cancer cases and matched controls, which deserve further investigation. The inverse relationship between EPA and colorectal cancer is in line with the repeatedly reported protective effect of fish consumption on colorectal cancer risk. Impact: These findings add to the evidence on colorectal cancer prevention.
- Published
- 2021
21. Development and validation of a lifestyle-based model for colorectal cancer risk prediction: the LiFeCRC score
- Author
-
Aleksandrova, K. Reichmann, R. Kaaks, R. Jenab, M. Bueno-de-Mesquita, H.B. Dahm, C.C. Eriksen, A.K. Tjønneland, A. Artaud, F. Boutron-Ruault, M.-C. Severi, G. Hüsing, A. Trichopoulou, A. Karakatsani, A. Peppa, E. Panico, S. Masala, G. Grioni, S. Sacerdote, C. Tumino, R. Elias, S.G. May, A.M. Borch, K.B. Sandanger, T.M. Skeie, G. Sánchez, M.-J. Huerta, J.M. Sala, N. Gurrea, A.B. Quirós, J.R. Amiano, P. Berntsson, J. Drake, I. van Guelpen, B. Harlid, S. Key, T. Weiderpass, E. Aglago, E.K. Cross, A.J. Tsilidis, K.K. Riboli, E. Gunter, M.J.
- Abstract
Background: Nutrition and lifestyle have been long established as risk factors for colorectal cancer (CRC). Modifiable lifestyle behaviours bear potential to minimize long-term CRC risk; however, translation of lifestyle information into individualized CRC risk assessment has not been implemented. Lifestyle-based risk models may aid the identification of high-risk individuals, guide referral to screening and motivate behaviour change. We therefore developed and validated a lifestyle-based CRC risk prediction algorithm in an asymptomatic European population. Methods: The model was based on data from 255,482 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study aged 19 to 70 years who were free of cancer at study baseline (1992–2000) and were followed up to 31 September 2010. The model was validated in a sample comprising 74,403 participants selected among five EPIC centres. Over a median follow-up time of 15 years, there were 3645 and 981 colorectal cancer cases in the derivation and validation samples, respectively. Variable selection algorithms in Cox proportional hazard regression and random survival forest (RSF) were used to identify the best predictors among plausible predictor variables. Measures of discrimination and calibration were calculated in derivation and validation samples. To facilitate model communication, a nomogram and a web-based application were developed. Results: The final selection model included age, waist circumference, height, smoking, alcohol consumption, physical activity, vegetables, dairy products, processed meat, and sugar and confectionary. The risk score demonstrated good discrimination overall and in sex-specific models. Harrell’s C-index was 0.710 in the derivation cohort and 0.714 in the validation cohort. The model was well calibrated and showed strong agreement between predicted and observed risk. Random survival forest analysis suggested high model robustness. Beyond age, lifestyle data led to improved model performance overall (continuous net reclassification improvement = 0.307 (95% CI 0.264–0.352)), and especially for young individuals below 45 years (continuous net reclassification improvement = 0.364 (95% CI 0.084–0.575)). Conclusions: LiFeCRC score based on age and lifestyle data accurately identifies individuals at risk for incident colorectal cancer in European populations and could contribute to improved prevention through motivating lifestyle change at an individual level. © 2020, The Author(s).
- Published
- 2021
22. The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium
- Author
-
Guida, F., Tan, V.Y., Corbin, L.J., Smith-Byrne, K., Alcala, K., Langenberg, C., Stewart, I.D., Butterworth, A.S., Surendran, P., Achaintre, D., Adamski, J., Exezarreta, P.A., Bergmann, M.M., Bull, C.J., Dahm, C.C., Gicquiau, A., Giles, G.G., Gunter, M.J., Haller, T., Langhammer, A., Larose, T.L., Ljungberg, B., Metspalu, A., Milne, R.L., Muller, D.C., Nøst, T.H., Sørgjerd, E.P., Prehn, C., Riboli, E., Rinaldi, S., Rothwell, J.A., Scalbert, A., Schmidt, J.A., Severi, G., Sieri, S., Vermeulen, R., Vincent, E.E., Waldenberger, M., Timpson, N.J., Johansson, M., Afd. Theologie, Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Langenberg, Claudia [0000-0002-5017-7344], Butterworth, Adam [0000-0002-6915-9015], Apollo - University of Cambridge Repository, Cancer Research UK, Guida, Florence [0000-0002-9652-2430], Tan, Vanessa Y. [0000-0001-7938-127X], Corbin, Laura J. [0000-0002-4032-9500], Alcala, Karine [0000-0003-2308-9880], Adamski, Jerzy [0000-0001-9259-0199], Bull, Caroline J. [0000-0002-2176-5120], Dahm, Christina C. [0000-0003-0481-2893], Giles, Graham G. [0000-0003-4946-9099], Langhammer, Arnulf [0000-0001-5296-6673], Ljungberg, Börje [0000-0002-4121-3753], Milne, Roger L. [0000-0001-5764-7268], Nøst, Therese H. [0000-0001-6805-3094], Pettersen Sørgjerd, Elin [0000-0002-5995-2386], Prehn, Cornelia [0000-0002-1274-4715], Riboli, Elio [0000-0001-6795-6080], Rothwell, Joseph A. [0000-0002-6927-3360], Scalbert, Augustin [0000-0001-6651-6710], Schmidt, Julie A. [0000-0002-7733-8750], Severi, Gianluca [0000-0001-7157-419X], Sieri, Sabina [0000-0001-5201-172X], Vincent, Emma E. [0000-0002-8917-7384], Timpson, Nicholas J. [0000-0002-7141-9189], Johansson, Mattias [0000-0002-3116-5081], Tan, Vanessa Y [0000-0001-7938-127X], Corbin, Laura J [0000-0002-4032-9500], Bull, Caroline J [0000-0002-2176-5120], Dahm, Christina C [0000-0003-0481-2893], Giles, Graham G [0000-0003-4946-9099], Milne, Roger L [0000-0001-5764-7268], Muller, David C [0000-0002-2350-0417], Nøst, Therese H [0000-0001-6805-3094], Rothwell, Joseph A [0000-0002-6927-3360], Schmidt, Julie A [0000-0002-7733-8750], Vincent, Emma E [0000-0002-8917-7384], Timpson, Nicholas J [0000-0002-7141-9189], Afd. Theologie, Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, and dIRAS RA-2
- Subjects
Male ,Epidemiology ,Single Nucleotide Polymorphisms ,Physiology ,Biochemistry ,Body Mass Index ,0302 clinical medicine ,Risk Factors ,Metabolites ,Medicine ,Prospective Studies ,Prospective cohort study ,11 Medical and Health Sciences ,2. Zero hunger ,Medicine(all) ,0303 health sciences ,Cancer Risk Factors ,Incidence ,Neurochemistry ,General Medicine ,Neurotransmitters ,Middle Aged ,Kidney Neoplasms ,3. Good health ,Europe ,Oncology ,Nephrology ,030220 oncology & carcinogenesis ,Renal Cancer ,Metabolome ,Female ,Metabolic Pathways ,Metabolic Labeling ,ICEP ,Glutamate ,Research Article ,Victoria ,Risk Assessment ,03 medical and health sciences ,General & Internal Medicine ,Genetics ,Xenobiotic Metabolism ,Humans ,Metabolomics ,Obesity ,Risk factor ,Molecular Biology Techniques ,Molecular Biology ,030304 developmental biology ,Aged ,Medicine and health sciences ,Cancer och onkologi ,Biology and life sciences ,business.industry ,Case-control study ,Cancer ,Odds ratio ,Mendelian Randomization Analysis ,medicine.disease ,Research and analysis methods ,Metabolism ,Cell Labeling ,Medical Risk Factors ,Cancer and Oncology ,Case-Control Studies ,business ,Kidney cancer ,Body mass index ,Biomarkers ,Neuroscience - Abstract
Background Excess bodyweight and related metabolic perturbations have been implicated in kidney cancer aetiology, but the specific molecular mechanisms underlying these relationships are poorly understood. In this study, we sought to identify circulating metabolites that predispose kidney cancer and to evaluate the extent to which they are influenced by body mass index (BMI). Methods and findings We assessed the association between circulating levels of 1,416 metabolites and incident kidney cancer using pre-diagnostic blood samples from up to 1,305 kidney cancer case–control pairs from 5 prospective cohort studies. Cases were diagnosed on average 8 years after blood collection. We found 25 metabolites robustly associated with kidney cancer risk. In particular, 14 glycerophospholipids (GPLs) were inversely associated with risk, including 8 phosphatidylcholines (PCs) and 2 plasmalogens. The PC with the strongest association was PC ae C34:3 with an odds ratio (OR) for 1 standard deviation (SD) increment of 0.75 (95% confidence interval [CI]: 0.68 to 0.83, p = 2.6 × 10−8). In contrast, 4 amino acids, including glutamate (OR for 1 SD = 1.39, 95% CI: 1.20 to 1.60, p = 1.6 × 10−5), were positively associated with risk. Adjusting for BMI partly attenuated the risk association for some—but not all—metabolites, whereas other known risk factors of kidney cancer, such as smoking and alcohol consumption, had minimal impact on the observed associations. A mendelian randomisation (MR) analysis of the influence of BMI on the blood metabolome highlighted that some metabolites associated with kidney cancer risk are influenced by BMI. Specifically, elevated BMI appeared to decrease levels of several GPLs that were also found inversely associated with kidney cancer risk (e.g., −0.17 SD change [ßBMI] in 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) levels per SD change in BMI, p = 3.4 × 10−5). BMI was also associated with increased levels of glutamate (ßBMI: 0.12, p = 1.5 × 10−3). While our results were robust across the participating studies, they were limited to study participants of European descent, and it will, therefore, be important to evaluate if our findings can be generalised to populations with different genetic backgrounds. Conclusions This study suggests a potentially important role of the blood metabolome in kidney cancer aetiology by highlighting a wide range of metabolites associated with the risk of developing kidney cancer and the extent to which changes in levels of these metabolites are driven by BMI—the principal modifiable risk factor of kidney cancer., In a case-control study, Florence Guida and colleagues identify metabolites associated with risk of kidney cancer, and use Mendelian randomization techniques to study the role of body mass index in this relationship., Author summary Why was this study done? Several modifiable risk factors have been established for kidney cancer, among which elevated body mass index (BMI) and obesity are central. The biological mechanisms underlying these relationships are poorly understood, but obesity-related metabolic perturbations may be important. What did the researchers do and find? We looked at the association between kidney cancer and the levels of 1,416 metabolites measured in blood on average 8 years before the disease onset. The study included 1,305 kidney cancer cases and 1,305 healthy controls. We found 25 metabolites robustly associated with kidney cancer risk. Specifically, multiple glycerophospholipids (GPLs) were inversely associated with risk, while several amino acids were positively associated with risk. Accounting for BMI highlighted that some—but not all—metabolites associated with kidney cancer risk are influenced by BMI. What do these findings mean? These findings illustrate the potential utility of prospectively measured metabolites in helping us to understand the aetiology of kidney cancer. By examining overlap between the metabolomic profile of prospective risk of kidney cancer and that of modifiable risk factors for the disease—in this case BMI—we can begin to identify biological pathways relevant to disease onset.
- Published
- 2021
23. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight
- Author
-
Iurilli, M.L.C. Zhou, B. Bennett, J.E. Carrillo-Larco, R.M. Sophiea, M.K. Rodriguez-Martinez, A. Bixby, H. Solomon, B.D. Taddei, C. Danaei, G. Di Cesare, M. Stevens, G.A. Riley, L.M. Savin, S. Cowan, M.J. Bovet, P. Damasceno, A. Chirita-Emandi, A. Hayes, A.J. Ikeda, N. Jackson, R.T. Khang, Y.-H. Laxmaiah, A. Liu, J. Miranda, J.J. Saidi, O. Sebert, S. Sorić, M. Starc, G. Gregg, E.W. Abarca-Gómez, L. Abdeen, Z.A. Abdrakhmanova, S. Ghaffar, S.A. Rahim, H.F.A. Abu-Rmeileh, N.M. Garba, J.A. Acosta-Cazares, B. Adams, R.J. Aekplakorn, W. Afsana, K. Afzal, S. Agdeppa, I.A. Aghazadeh-Attari, J. Aguilar-Salinas, C.A. Agyemang, C. Ahmad, M.H. Ahmad, N.A. Ahmadi, A. Ahmadi, N. Ahmed, S.H. Ahrens, W. Aitmurzaeva, G. Ajlouni, K. Al-Hazzaa, H.M. Al-Lahou, B. Al-Raddadi, R. Alarouj, M. AlBuhairan, F. AlDhukair, S. Ali, M.M. Alkandari, A. Alkerwi, A. Allin, K. Alvarez-Pedrerol, M. Aly, E. Amarapurkar, D.N. Amiri, P. Amougou, N. Amouyel, P. Andersen, L.B. Anderssen, S.A. Ängquist, L. Anjana, R.M. Ansari-Moghaddam, A. Aounallah-Skhiri, H. Araújo, J. Ariansen, I. Aris, T. Arku, R.E. Arlappa, N. Aryal, K.K. Aspelund, T. Assah, F.K. Assunção, M.C.F. Aung, M.S. Auvinen, J. Mária Avdicová Avi, S. Azevedo, A. Azimi-Nezhad, M. Azizi, F. Azmin, M. Babu, B.V. Bæksgaard Jørgensen, M. Baharudin, A. Bahijri, S. Baker, J.L. Balakrishna, N. Bamoshmoosh, M. Banach, M. Bandosz, P. Banegas, J.R. Baran, J. Barbagallo, C.M. Barceló, A. Barkat, A. Barros, A.J.D. Barros, M.V.G. Basit, A. Bastos, J.L.D. Bata, I. Batieha, A.M. Batista, R.L. Battakova, Z. Batyrbek, A. Baur, L.A. Beaglehole, R. Bel-Serrat, S. Belavendra, A. Romdhane, H.B. Benedics, J. Benet, M. Bergh, I.H. Berkinbayev, S. Bernabe-Ortiz, A. Bernotiene, G. Bettiol, H. Bezerra, J. Bhagyalaxmi, A. Bharadwaj, S. Bhargava, S.K. Bhutta, Z.A. Bi, H. Bi, Y. Bia, D. Lele, E.C.B. Bikbov, M.M. Bista, B. Bjelica, D.J. Bjerregaard, P. Bjertness, E. Bjertness, M.B. Björkelund, C. Bloch, K.V. Blokstra, A. Bo, S. Bobak, M. Boddy, L.M. Boehm, B.O. Boeing, H. Boggia, J.G. Bogova, E. Boissonnet, C.P. Bojesen, S.E. Bonaccio, M. Bongard, V. Bonilla-Vargas, A. Bopp, M. Borghs, H. Braeckevelt, L. Braeckman, L. Bragt, M.C.E. Brajkovich, I. Branca, F. Breckenkamp, J. Breda, J. Brenner, H. Brewster, L.M. Brian, G.R. Brinduse, L. Brophy, S. Bruno, G. Bueno-de-Mesquita, H.B. Bugge, A. Buoncristiano, M. Burazeri, G. Burns, C. de León, A.C. Cacciottolo, J. Cai, H. Cama, T. Cameron, C. Camolas, J. Can, G. Candido, A.P.C. Cañete, F. Capanzana, M.V. Capková, N. Capuano, E. Capuano, V. Cardol, M. Cardoso, V.C. Carlsson, A.C. Carmuega, E. Carvalho, J. Casajús, J.A. Casanueva, F.F. Celikcan, E. Censi, L. Cervantes-Loaiza, M. Cesar, J.A. Chamukuttan, S. Chan, A.W. Chan, Q. Chaturvedi, H.K. Chaturvedi, N. Rahim, N.C.A. Chee, M.L. Chen, C.-J. Chen, F. Chen, H. Chen, S. Chen, Z. Cheng, C.-Y. Cheraghian, B. Chetrit, A. Chikova-Iscener, E. Chiolero, A. Chiou, S.-T. Chirlaque, M.-D. Cho, B. Christensen, K. Christofaro, D.G. Chudek, J. Cifkova, R. Cilia, M. Cinteza, E. Claessens, F. Clarke, J. Clays, E. Cohen, E. Concin, H. Confortin, S.C. Cooper, C. Coppinger, T.C. Corpeleijn, E. Costanzo, S. Cottel, D. Cowell, C. Craig, C.L. Crampin, A.C. Crujeiras, A.B. Csilla, S. Cucu, A.M. Cui, L. Cureau, F.V. Czenczek-Lewandowska, E. D’Arrigo, G. d’Orsi, E. Dacica, L. Dal Re Saavedra, M.A. Dallongeville, J. Damsgaard, C.T. Dankner, R. Dantoft, T.M. Dasgupta, P. Dastgiri, S. Dauchet, L. Davletov, K. De Backer, G. De Bacquer, D. de Gaetano, G. De Henauw, S. de Oliveira, P.D. De Ridder, D. De Ridder, K. de Rooij, S.R. De Smedt, D. Deepa, M. Deev, A.D. DeGennaro, V., Jr Dehghan, A. Delisle, H. Delpeuch, F. Demarest, S. Dennison, E. Dereń, K. Deschamps, V. Dhimal, M. Di Castelnuovo, A.F. Dias-da-Costa, J.S. Díaz-Sánchez, M.E. Diaz, A. Dika, Z. Djalalinia, S. Djordjic, V. Do, H.T.P. Dobson, A.J. Donati, M.B. Donfrancesco, C. Donoso, S.P. Döring, A. Dorobantu, M. Dorosty, A.R. Doua, K. Dragano, N. Drygas, W. Duan, J.L. Duante, C.A. Duboz, P. Duda, R.B. Duleva, V. Dulskiene, V. Dumith, S.C. Dushpanova, A. Dzerve, V. Dziankowska-Zaborszczyk, E. Eddie, R. Eftekhar, E. Egbagbe, E.E. Eggertsen, R. Eghtesad, S. Eiben, G. Ekelund, U. El-Khateeb, M. Ati, J.E. Eldemire-Shearer, D. Eliasen, M. Elliott, P. Engle-Stone, R. Enguerran, M. Erasmus, R.T. Erbel, R. Erem, C. Eriksen, L. Eriksson, J.G. Escobedo-de la Peña, J. Eslami, S. Esmaeili, A. Evans, A. Faeh, D. Fakhretdinova, A.A. Fall, C.H. Faramarzi, E. Farjam, M. Sant’Angelo, V.F. Farzadfar, F. Fattahi, M.R. Fawwad, A. Felix-Redondo, F.J. Ferguson, T.S. Fernandes, R.A. Fernández-Bergés, D. Ferrante, D. Ferrao, T. Ferrari, M. Ferrario, M.M. Ferreccio, C. Ferrer, E. Ferrieres, J. Figueiró, T.H. Fijalkowska, A. Fink, G. Fischer, K. Foo, L.H. Forsner, M. Fouad, H.M. Francis, D.K. Maria do Carmo Franco Frikke-Schmidt, R. Frontera, G. Fuchs, F.D. Fuchs, S.C. Fujiati, I.I. Fujita, Y. Fumihiko, M. Furusawa, T. Gaciong, Z. Gafencu, M. Galbarczyk, A. Galenkamp, H. Galeone, D. Galfo, M. Galvano, F. Gao, J. Garcia-de-la-Hera, M. García-Solano, M. Gareta, D. Garnett, S.P. Gaspoz, J.-M. Gasull, M. Gaya, A.C.A. Gaya, A.R. Gazzinelli, A. Gehring, U. Geiger, H. Geleijnse, J.M. Ghanbari, A. Ghasemi, E. Gheorghe-Fronea, O.-F. Giampaoli, S. Gianfagna, F. Gill, T.K. Giovannelli, J. Gironella, G. Giwercman, A. Gkiouras, K. Godos, J. Gogen, S. Goldberg, M. Goldsmith, R.A. Goltzman, D. Gómez, S.F. Gomula, A. da Silva, B.G.C. Gonçalves, H. Gonzalez-Chica, D.A. Gonzalez-Gross, M. González-Leon, M. González-Rivas, J.P. González-Villalpando, C. González-Villalpando, M.-E. Gonzalez, A.R. Gottrand, F. Graça, A.P. Graff-Iversen, S. Grafnetter, D. Grajda, A. Grammatikopoulou, M.G. Gregor, R.D. Grodzicki, T. Grøholt, E.K. Grøntved, A. Grosso, G. Gruden, G. Gu, D. Gualdi-Russo, E. Guallar-Castillón, P. Gualtieri, A. Gudmundsson, E.F. Gudnason, V. Guerrero, R. Guessous, I. Guimaraes, A.L. Gulliford, M.C. Gunnlaugsdottir, J. Gunter, M.J. Guo, X.-H. Guo, Y. Gupta, P.C. Gupta, R. Gureje, O. Gurzkowska, B. Gutiérrez-González, E. Gutierrez, L. Gutzwiller, F. Ha, S. Hadaegh, F. Hadjigeorgiou, C.A. Haghshenas, R. Hakimi, H. Halkjær, J. Hambleton, I.R. Hamzeh, B. Hange, D. Hanif, A.A.M. Hantunen, S. Hao, J. Kumar, R.H. Hashemi-Shahri, S.M. Hassapidou, M. Hata, J. Haugsgjerd, T. He, J. He, Y. He, Y. Heidinger-Felso, R. Heinen, M. Hejgaard, T. Hendriks, M.E. dos Santos Henrique, R. Henriques, A. Cadena, L.H. Herrala, S. Herrera, V.M. Herter-Aeberli, I. Heshmat, R. Hill, A.G. Ho, S.Y. Ho, S.C. Hobbs, M. Holdsworth, M. Homayounfar, R. Homs, C. Hopman, W.M. Horimoto, A.R.V.R. Hormiga, C.M. Horta, B.L. Houti, L. Howitt, C. Htay, T.T. Htet, A.S. Htike, M.M.T. Hu, Y. Huerta, J.M. Huhtaniemi, I.T. Huiart, L. Petrescu, C.H. Huisman, M. Husseini, A. Huu, C.N. Huybrechts, I. Hwalla, N. Hyska, J. Iacoviello, L. Ibarluzea, J.M. Ibrahim, M.M. Wong, N.I. Ikram, M.A. Iotova, V. Irazola, V.E. Ishida, T. Islam, M. Islam, S.M.S. Iwasaki, M. Jacobs, J.M. Jaddou, H.Y. Jafar, T. James, K. Jamil, K.M. Jamrozik, K. Janszky, I. Janus, E. Jarani, J. Jarvelin, M.-R. Jasienska, G. Jelakovic, A. Jelakovic, B. Jennings, G. Jha, A.K. Jiang, C.Q. Jimenez, R.O. Jöckel, K.-H. Joffres, M. Johansson, M. Jokelainen, J.J. Jonas, J.B. Jonnagaddala, J. Jørgensen, T. Joshi, P. Joukar, F. Jovic, D.P. Jóźwiak, J.J. Juolevi, A. Jurak, G. Simina, I.J. Juresa, V. Kaaks, R. Kaducu, F.O. Kafatos, A. Kajantie, E.O. Kalmatayeva, Z. Kalter-Leibovici, O. Kameli, Y. Kampmann, F.B. Kanala, K.R. Kannan, S. Kapantais, E. Karakosta, A. Kårhus, L.L. Karki, K.B. Katibeh, M. Katz, J. Katzmarzyk, P.T. Kauhanen, J. Kaur, P. Kavousi, M. Kazakbaeva, G.M. Keil, U. Boker, L.K. Keinänen-Kiukaanniemi, S. Kelishadi, R. Kelleher, C. Kemper, H.C.G. Kengne, A.P. Keramati, M. Kerimkulova, A. Kersting, M. Key, T. Khader, Y.S. Khalili, D. Khaw, K.-T. Kheiri, B. Kheradmand, M. Khosravi, A. Khouw, I.M.S.L. Kiechl-Kohlendorfer, U. Kiechl, S. Killewo, J. Kim, D.W. Kim, H.C. Kim, J. Kindblom, J.M. Klakk, H. Klimek, M. Klimont, J. Klumbiene, J. Knoflach, M. Koirala, B. Kolle, E. Kolsteren, P. König, J. Korpelainen, R. Korrovits, P. Korzycka, M. Kos, J. Koskinen, S. Kouda, K. Kovacs, V.A. Kowlessur, S. Koziel, S. Kratenova, J. Kratzer, W. Kriemler, S. Kristensen, P.L. Krokstad, S. Kromhout, D. Kruger, H.S. Kubinova, R. Kuciene, R. Kujala, U.M. Kujundzic, E. Kulaga, Z. Kumar, R.K. Kunešová, M. Kurjata, P. Kusuma, Y.S. Kuulasmaa, K. Kyobutungi, C. La, Q.N. Laamiri, F.Z. Laatikainen, T. Lachat, C. Laid, Y. Lam, T.H. Lambrinou, C.-P. Landais, E. Lanska, V. Lappas, G. Larijani, B. Latt, T.S. Lauria, L. Lazo-Porras, M. Le Coroller, G. Bao, K.L.N. Le Port, A. Le, T.D. Lee, J. Lee, J. Lee, P.H. Lehmann, N. Lehtimäki, T. Lemogoum, D. Levitt, N.S. Li, Y. Liivak, M. Lilly, C.L. Lim, W.-Y. Lima-Costa, M.F. Lin, H.-H. Lin, X. Lin, Y.-T. Lind, L. Linneberg, A. Lissner, L. Litwin, M. Liu, L. Lo, W.-C. Loit, H.-M. Long, K.Q. Lopes, L. Lopes, O. Lopez-Garcia, E. Lopez, T. Lotufo, P.A. Lozano, J.E. Lukrafka, J.L. Luksiene, D. Lundqvist, A. Lundqvist, R. Lunet, N. Lunogelo, C. Lustigová, M. Łuszczki, E. Ma, G. Ma, J. Ma, X. Machado-Coelho, G.L.L. Machado-Rodrigues, A.M. Macieira, L.M. Madar, A.A. Maggi, S. Magliano, D.J. Magnacca, S. Magriplis, E. Mahasampath, G. Maire, B. Majer, M. Makdisse, M. Mäki, P. Malekzadeh, F. Malekzadeh, R. Malhotra, R. Rao, K.M. Malyutina, S.K. Maniego, L.V. Manios, Y. Mann, J.I. Mansour-Ghanaei, F. Manzato, E. Margozzini, P. Markaki, A. Markey, O. Ioannidou, E.M. Marques-Vidal, P. Marques, L.P. Marrugat, J. Martin-Prevel, Y. Martin, R. Martorell, R. Martos, E. Maruszczak, K. Marventano, S. Mascarenhas, L.P. Masoodi, S.R. Mathiesen, E.B. Mathur, P. Matijasevich, A. Matsha, T.E. Mavrogianni, C. Mazur, A. Mbanya, J.C.N. McFarlane, S.R. McGarvey, S.T. McKee, M. McLachlan, S. McLean, R.M. McLean, S.B. McNulty, B.A. Benchekor, S.M. Medzioniene, J. Mehdipour, P. Mehlig, K. Mehrparvar, A.H. Meirhaeghe, A. Meisfjord, J. Meisinger, C. Menezes, A.M.B. Menon, G.R. Mensink, G.B.M. Menzano, M.T. Mereke, A. Meshram, I.I. Metspalu, A. Meyer, H.E. Mi, J. Michaelsen, K.F. Michels, N. Mikkel, K. Milkowska, K. Miller, J.C. Minderico, C.S. Mini, G.K. Miquel, J.F. Mirjalili, M.R. Mirkopoulou, D. Mirrakhimov, E. Mišigoj-Durakovic, M. Mistretta, A. Mocanu, V. Modesti, P.A. Moghaddam, S.S. Mohajer, B. Mohamed, M.K. Mohamed, S.F. Mohammad, K. Mohammadi, Z. Mohammadifard, N. Mohammadpourhodki, R. Mohan, V. Mohanna, S. Yusoff, M.F.M. Mohebbi, I. Mohebi, F. Moitry, M. Molbo, D. Møllehave, L.T. Møller, N.C. Molnár, D. Momenan, A. Mondo, C.K. Monroy-Valle, M. Monterrubio-Flores, E. Monyeki, K.D.K. Moon, J.S. Moosazadeh, M. Moreira, L.B. Morejon, A. Moreno, L.A. Morgan, K. Morin, S.N. Mortensen, E.L. Moschonis, G. Mossakowska, M. Mostafa, A. Mota-Pinto, A. Mota, J. Motlagh, M.E. Motta, J. Moura-dos-Santos, M.A. Mridha, M.K. Msyamboza, K.P. Mu, T.T. Muc, M. Mugoša, B. Muiesan, M.L. Mukhtorova, P. Müller-Nurasyid, M. Murphy, N. Mursu, J. Murtagh, E.M. Musa, K.I. Milanovic, S.M. Musil, V. Mustafa, N. Nabipour, I. Naderimagham, S. Nagel, G. Naidu, B.M. Najafi, F. Nakamura, H. Námešná, J. Nang, E.E.K. Nangia, V.B. Nankap, M. Narake, S. Nardone, P. Nauck, M. Neal, W.A. Nejatizadeh, A. Nekkantti, C. Nelis, K. Nelis, L. Nenko, I. Neovius, M. Nervi, F. Nguyen, C.T. Nguyen, N.D. Nguyen, Q.N. Nieto-Martínez, R.E. Nikitin, Y.P. Ning, G. Ninomiya, T. Nishtar, S. Noale, M. Noboa, O.A. Nogueira, H. Norat, T. Nordendahl, M. Nordestgaard, B.G. Noto, D. Nowak-Szczepanska, N. Al Nsour, M. Nuhoglu, I. Nurk, E. O’Neill, T.W. O’Reilly, D. Obreja, G. Ochimana, C. Ochoa-Avilés, A.M. Oda, E. Oh, K. Ohara, K. Ohlsson, C. Ohtsuka, R. Olafsson, O. Olinto, M.T.A. Oliveira, I.O. Omar, M.A. Onat, A. Ong, S.K. Ono, L.M. Ordunez, P. Ornelas, R. Ortiz, A.P. Ortiz, P.J. Osler, M. Osmond, C. Ostojic, S.M. Ostovar, A. Otero, J.A. Overvad, K. Owusu-Dabo, E. Paccaud, F.M. Padez, C. Pagkalos, I. Pahomova, E. de Paiva, K.M. Pajak, A. Palli, D. Palloni, A. Palmieri, L. Pan, W.-H. Panda-Jonas, S. Pandey, A. Panza, F. Papandreou, D. Park, S.-W. Park, S. Parnell, W.R. Parsaeian, M. Pascanu, I.M. Pasquet, P. Patel, N.D. Pecin, I. Pednekar, M.S. Peer, N. Pei, G. Peixoto, S.V. Peltonen, M. Pereira, A.C. Peres, M.A. Pérez-Farinós, N. Pérez, C.M. Peterkova, V. Peters, A. Petersmann, A. Petkeviciene, J. Petrauskiene, A. Pettenuzzo, E. Peykari, N. Pham, S.T. Pichardo, R.N. Pierannunzio, D. Pigeot, I. Pikhart, H. Pilav, A. Pilotto, L. Pistelli, F. Pitakaka, F. Piwonska, A. Pizarro, A.N. Plans-Rubió, P. Poh, B.K. Pohlabeln, H. Pop, R.M. Popovic, S.R. Porta, M. Posch, G. Poudyal, A. Poulimeneas, D. Pouraram, H. Pourfarzi, F. Pourshams, A. Poustchi, H. Pradeepa, R. Price, A.J. Price, J.F. Providencia, R. Puder, J.J. Pudule, I. Puhakka, S.E. Puiu, M. Punab, M. Qasrawi, R.F. Qorbani, M. Bao, T.Q. Radic, I. Radisauskas, R. Rahimikazerooni, S. Rahman, M. Rahman, M. Raitakari, O. Raj, M. Rakhimova, E. Rakhmatulloev, S. Rakovac, I. Rao, S.R. Ramachandran, A. Ramke, J. Ramos, E. Ramos, R. Rampal, L. Rampal, S. Rarra, V. Rascon-Pacheco, R.A. Rasmussen, M. Rech, C.R. Redon, J. Reganit, P.F.M. Regecová, V. Revilla, L. Rezaianzadeh, A. Ribas-Barba, L. Ribeiro, R. Riboli, E. Richter, A. Rigo, F. Rinaldo, N. de Wit, T.F.R. Rito, A. Ritti-Dias, R.M. Rivera, J.A. Robitaille, C. Roccaldo, R. Rodrigues, D. Rodríguez-Artalejo, F. del Cristo Rodriguez-Perez, M. Rodríguez-Villamizar, L.A. Roggenbuck, U. Rojas-Martinez, R. Rojroongwasinkul, N. Romaguera, D. Romeo, E.L. Rosario, R.V. Rosengren, A. Rouse, I. Roy, J.G.R. Rubinstein, A. Rühli, F.J. Ruidavets, J.-B. Ruiz-Betancourt, B.S. Ruiz-Castell, M. Moreno, E.R. Rusakova, I.A. Jonsson, K.R. Russo, P. Rust, P. Rutkowski, M. Sabanayagam, C. Sacchini, E. Sachdev, H.S. Sadjadi, A. Safarpour, A.R. Safiri, S. Saki, N. Salanave, B. Martinez, E.S. Salmerón, D. Salomaa, V. Salonen, J.T. Salvetti, M. Samoutian, M. Sánchez-Abanto, J. Sans, S. Marina, L.S. Santos, D.A. Santos, I.S. Santos, L.C. Santos, M.P. Santos, O. Santos, R. Sanz, S.S. Saramies, J.L. Sardinha, L.B. Sarrafzadegan, N. Sathish, T. Saum, K.-U. Savva, S. Savy, M. Sawada, N. Sbaraini, M. Scazufca, M. Schaan, B.D. Rosario, A.S. Schargrodsky, H. Schienkiewitz, A. Schipf, S. Schmidt, C.O. Schmidt, I.M. Schnohr, P. Schöttker, B. Schramm, S. Schramm, S. Schröder, H. Schultsz, C. Schutte, A.E. Sein, A.A. Selamat, R. Sember, V. Sen, A. Senbanjo, I.O. Sepanlou, S.G. Sequera, V. Serra-Majem, L. Servais, J. Ševcíková, L. Shalnova, S.A. Shamah-Levy, T. Shamshirgaran, M. Shanthirani, C.S. Sharafkhah, M. Sharma, S.K. Shaw, J.E. Shayanrad, A. Shayesteh, A.A. Shengelia, L. Shi, Z. Shibuya, K. Shimizu-Furusawa, H. Shin, D.W. Shirani, M. Shiri, R. Shrestha, N. Si-Ramlee, K. Siani, A. Siantar, R. Sibai, A.M. Silva, A.M. Silva, D.A.S. Simon, M. Simons, J. Simons, L.A. Sjöberg, A. Sjöström, M. Skodje, G. Slowikowska-Hilczer, J. Slusarczyk, P. Smeeth, L. So, H.-K. Soares, F.C. Sobek, G. Sobngwi, E. Sodemann, M. Söderberg, S. Soekatri, M.Y.E. Soemantri, A. Sofat, R. Solfrizzi, V. Somi, M.H. Sonestedt, E. Song, Y. Sørensen, T.I.A. Sørgjerd, E.P. Jérome, C.S. Soto-Rojas, V.E. Soumaré, A. Sovic, S. Sparboe-Nilsen, B. Sparrenberger, K. Spinelli, A. Spiroski, I. Staessen, J.A. Stamm, H. Stathopoulou, M.G. Staub, K. Stavreski, B. Steene-Johannessen, J. Stehle, P. Stein, A.D. Stergiou, G.S. Stessman, J. Stevanovic, R. Stieber, J. Stöckl, D. Stocks, T. Stokwiszewski, J. Stoyanova, E. Stratton, G. Stronks, K. Strufaldi, M.W. Sturua, L. Suárez-Medina, S. Suka, M. Sun, C.-A. Sundström, J. Sung, Y.-T. Sunyer, J. Suriyawongpaisal, P. Swinburn, B.A. Sy, R.G. Syddall, H.E. Sylva, R.C. Szklo, M. Szponar, L. Tai, E.S. Tammesoo, M.-L. Tamosiunas, A. Tan, E.J. Tang, X. Tanrygulyyeva, M. Tanser, F. Tao, Y. Tarawneh, M.R. Tarp, J. Tarqui-Mamani, C.B. Braunerová, R.T. Taylor, A. Taylor, J. Tchibindat, F. Tebar, W.R. Tell, G.S. Tello, T. Tham, Y.C. Thankappan, K.R. Theobald, H. Theodoridis, X. Thijs, L. Thomas, N. Thuesen, B.H. Tichá, L. Timmermans, E.J. Tjonneland, A. Tolonen, H.K. Tolstrup, J.S. Topbas, M. Topór-Madry, R. Torheim, L.E. Tormo, M.J. Tornaritis, M.J. Torrent, M. Torres-Collado, L. Toselli, S. Touloumi, G. Traissac, P. Tran, T.T.-H. Trichopoulos, D. Trichopoulou, A. Trinh, D.T.H. Trivedi, A. Tshepo, L. Tsigga, M. Tsugane, S. Tuliakova, A.M. Tulloch-Reid, M.K. Tullu, F. Tuomainen, T.-P. Tuomilehto, J. Turley, M.L. Twig, G. Tynelius, P. Tzotzas, T. Tzourio, C. Ueda, P. Ugel, E. Ukoli, F.A.M. Ulmer, H. Unal, B. Usupova, Z. Uusitalo, H.M.T. Uysal, N. Vaitkeviciute, J. Valdivia, G. Vale, S. Valvi, D. van Dam, R.M. Van der Heyden, J. van der Schouw, Y.T. Van Herck, K. Van Minh, H. Van Schoor, N.M. van Valkengoed, I.G.M. Vanderschueren, D. Vanuzzo, D. Varbo, A. Varela-Moreiras, G. Varona-Pérez, P. Vasan, S.K. Vega, T. Veidebaum, T. Velasquez-Melendez, G. Velika, B. Veronesi, G. Verschuren, W.M.M. Victora, C.G. Viegi, G. Viet, L. Villalpando, S. Vineis, P. Vioque, J. Virtanen, J.K. Visser, M. Visvikis-Siest, S. Viswanathan, B. Vladulescu, M. Vlasoff, T. Vocanec, D. Vollenweider, P. Völzke, H. Voutilainen, A. Voutilainen, S. Vrijheid, M. Vrijkotte, T.G.M. Wade, A.N. Wagner, A. Waldhör, T. Walton, J. Wambiya, E.O.A. Bebakar, A.M.W. Mohamud, W.N.W. de Souza Wanderley Júnior, R. Wang, M.-D. Wang, N. Wang, Q. Wang, X. Wang, Y.X. Wang, Y.-W. Wannamethee, S.G. Wareham, N. Weber, A. Wedderkopp, N. Weerasekera, D. Weghuber, D. Wei, W. Weres, A. Werner, B. Whincup, P.H. Widhalm, K. Widyahening, I.S. Wiecek, A. Wilks, R.J. Willeit, J. Willeit, P. Williams, J. Wilsgaard, T. Wojtyniak, B. Wong-McClure, R.A. Wong, A. Wong, J.E. Wong, T.Y. Woo, J. Woodward, M. Wu, F.C. Wu, J. Wu, L.J. Wu, S. Xu, H. Xu, L. Yaacob, N.A. Yamborisut, U. Yan, W. Yang, L. Yang, X. Yang, Y. Yardim, N. Yaseri, M. Yasuharu, T. Ye, X. Yiallouros, P.K. Yoosefi, M. Yoshihara, A. You, Q.S. You, S.-L. Younger-Coleman, N.O. Yusof, S.M. Yusoff, A.F. Zaccagni, L. Zafiropulos, V. Zainuddin, A.A. Zakavi, S.R. Zamani, F. Zambon, S. Zampelas, A. Zamrazilová, H. Zapata, M.E. Zargar, A.H. Zaw, K.K. Zdrojewski, T. Zejglicova, K. Vrkic, T.Z. Zeng, Y. Zhang, L. Zhang, Z.-Y. Zhao, D. Zhao, M.-H. Zhao, W. Zhen, S. Zheng, W. Zheng, Y. Zholdin, B. Zhou, M. Zhu, D. Zins, M. Zitt, E. Zocalo, Y. Cisneros, J.Z. Zuziak, M. Ezzati, M. Filippi, S. NCD Risk Factor Collaboration (NCD-RisC)
- Subjects
nutritional and metabolic diseases ,sense organs ,skin and connective tissue diseases - Abstract
From 1985 to 2016, the prevalence of underweight decreased, and that of obesity and severe obesity increased, in most regions, with significant variation in the magnitude of these changes across regions. We investigated how much change in mean body mass index (BMI) explains changes in the prevalence of underweight, obesity, and severe obesity in different regions using data from 2896 population-based studies with 187 million participants. Changes in the prevalence of underweight and total obesity, and to a lesser extent severe obesity, are largely driven by shifts in the distribution of BMI, with smaller contributions from changes in the shape of the distribution. In East and Southeast Asia and sub-Saharan Africa, the underweight tail of the BMI distribution was left behind as the distribution shifted. There is a need for policies that address all forms of malnutrition by making healthy foods accessible and affordable, while restricting unhealthy foods through fiscal and regulatory restrictions. © Copyright.
- Published
- 2021
24. Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies
- Author
-
Jayasekara, H. MacInnis, R.J. Lujan-Barroso, L. Mayen-Chacon, A.-L. Cross, A.J. Wallner, B. Palli, D. Ricceri, F. Pala, V. Panico, S. Tumino, R. Kühn, T. Kaaks, R. Tsilidis, K. Sánchez, M.-J. Amiano, P. Ardanaz, E. Chirlaque López, M.D. Merino, S. Rothwell, J.A. Boutron-Ruault, M.-C. Severi, G. Sternby, H. Sonestedt, E. Bueno-de-Mesquita, B. Boeing, H. Travis, R. Sandanger, T.M. Trichopoulou, A. Karakatsani, A. Peppa, E. Tjønneland, A. Yang, Y. Hodge, A.M. Mitchell, H. Haydon, A. Room, R. Hopper, J.L. Weiderpass, E. Gunter, M.J. Riboli, E. Giles, G.G. Milne, R.L. Agudo, A. English, D.R. Ferrari, P.
- Abstract
Alcohol consumption is causally linked to several cancers but the evidence for stomach cancer is inconclusive. In our study, the association between long-term alcohol intake and risk of stomach cancer and its subtypes was evaluated. We performed a pooled analysis of data collected at baseline from 491 714 participants in the European Prospective Investigation into Cancer and Nutrition and the Melbourne Collaborative Cohort Study. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for incident stomach cancer in relation to lifetime alcohol intake and group-based life course intake trajectories, adjusted for potential confounders including Helicobacter pylori infection. In all, 1225 incident stomach cancers (78% noncardia) were diagnosed over 7 094 637 person-years; 984 in 382 957 study participants with lifetime alcohol intake data (5 455 507 person-years). Although lifetime alcohol intake was not associated with overall stomach cancer risk, we observed a weak positive association with noncardia cancer (HR = 1.03, 95% CI: 1.00-1.06 per 10 g/d increment), with a HR of 1.50 (95% CI: 1.08-2.09) for ≥60 g/d compared to 0.1 to 4.9 g/d. A weak inverse association with cardia cancer (HR = 0.93, 95% CI: 0.87-1.00) was also observed. HRs of 1.48 (95% CI: 1.10-1.99) for noncardia and 0.51 (95% CI: 0.26-1.03) for cardia cancer were observed for a life course trajectory characterized by heavy decreasing intake compared to light stable intake (Phomogeneity =.02). These associations did not differ appreciably by smoking or H pylori infection status. Limiting alcohol use during lifetime, particularly avoiding heavy use during early adulthood, might help prevent noncardia stomach cancer. Heterogeneous associations observed for cardia and noncardia cancers may indicate etiologic differences. © 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
- Published
- 2021
25. Response to Li and Hopper.
- Author
-
Thomas M., Sakoda L.C., Hoffmeister M., Rosenthal E.A., Lee J.K., van Duijnhoven F.J.B., Platz E.A., Wu A.H., Dampier C.H., de la Chapelle A., Wolk A., Joshi A.D., Burnett-Hartman A., Gsur A., Lindblom A., Castells A., Win A.K., Namjou B., Van Guelpen B., Tangen C.M., He Q., Li C.I., Schafmayer C., Joshu C.E., Ulrich C.M., Bishop D.T., Buchanan D.D., Schaid D., Drew D.A., Muller D.C., Duggan D., Crosslin D.R., Albanes D., Giovannucci E.L., Larson E., Qu F., Mentch F., Giles G.G., Hakonarson H., Hampel H., Stanaway I.B., Figueiredo J.C., Huyghe J.R., Minnier J., Chang-Claude J., Hampe J., Harley J.B., Visvanathan K., Curtis K.R., Offit K., Li L., Le Marchand L., Vodickova L., Gunter M.J., Jenkins M.A., Slattery M.L., Lemire M., Woods M.O., Song M., Murphy N., Lindor N.M., Dikilitas O., Pharoah P.D.P., Campbell P.T., Newcomb P.A., Milne R.L., MacInnis R.J., Castellvi-Bel S., Ogino S., Berndt S.I., Bezieau S., Thibodeau S.N., Gallinger S.J., Zaidi S.H., Harrison T.A., Keku T.O., Hudson T.J., Vymetalkova V., Moreno V., Martin V., Arndt V., Wei W.-Q., Chung W., Su Y.-R., Hayes R.B., White E., Vodicka P., Casey G., Gruber S.B., Schoen R.E., Chan A.T., Potter J.D., Brenner H., Jarvik G.P., Corley D.A., Peters U., Hsu L., Thomas M., Sakoda L.C., Hoffmeister M., Rosenthal E.A., Lee J.K., van Duijnhoven F.J.B., Platz E.A., Wu A.H., Dampier C.H., de la Chapelle A., Wolk A., Joshi A.D., Burnett-Hartman A., Gsur A., Lindblom A., Castells A., Win A.K., Namjou B., Van Guelpen B., Tangen C.M., He Q., Li C.I., Schafmayer C., Joshu C.E., Ulrich C.M., Bishop D.T., Buchanan D.D., Schaid D., Drew D.A., Muller D.C., Duggan D., Crosslin D.R., Albanes D., Giovannucci E.L., Larson E., Qu F., Mentch F., Giles G.G., Hakonarson H., Hampel H., Stanaway I.B., Figueiredo J.C., Huyghe J.R., Minnier J., Chang-Claude J., Hampe J., Harley J.B., Visvanathan K., Curtis K.R., Offit K., Li L., Le Marchand L., Vodickova L., Gunter M.J., Jenkins M.A., Slattery M.L., Lemire M., Woods M.O., Song M., Murphy N., Lindor N.M., Dikilitas O., Pharoah P.D.P., Campbell P.T., Newcomb P.A., Milne R.L., MacInnis R.J., Castellvi-Bel S., Ogino S., Berndt S.I., Bezieau S., Thibodeau S.N., Gallinger S.J., Zaidi S.H., Harrison T.A., Keku T.O., Hudson T.J., Vymetalkova V., Moreno V., Martin V., Arndt V., Wei W.-Q., Chung W., Su Y.-R., Hayes R.B., White E., Vodicka P., Casey G., Gruber S.B., Schoen R.E., Chan A.T., Potter J.D., Brenner H., Jarvik G.P., Corley D.A., Peters U., and Hsu L.
- Published
- 2021
26. Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
- Author
-
Dimou N.L., Papadimitriou N., Mariosa D., Johansson M., Brennan P., Peters U., Chanock S.J., Purdue M., Bishop D.T., Gago-Dominquez M., Giles G.G., Moreno V., Platz E.A., Tangen C.M., Wolk A., Zheng W., Wu X., Campbell P.T., Giovannucci E., Lin Y., Gunter M.J., Murphy N., Dimou N.L., Papadimitriou N., Mariosa D., Johansson M., Brennan P., Peters U., Chanock S.J., Purdue M., Bishop D.T., Gago-Dominquez M., Giles G.G., Moreno V., Platz E.A., Tangen C.M., Wolk A., Zheng W., Wu X., Campbell P.T., Giovannucci E., Lin Y., Gunter M.J., and Murphy N.
- Abstract
Obesity is considered a chronic inflammatory state characterized by continued secretion of adipokines and cytokines. Experimental and epidemiological evidence indicates that circulating adipokines may be associated with the development of obesity-related cancers, but it is unclear if these associations are causal or confounded. We examined potential causal associations of specific adipokines (adiponectin, leptin, soluble leptin receptor [sOB-R] and plasminogen activator inhibitor-1 [PAI-1]) with five obesity-related cancers (colorectal, pancreatic, renal cell carcinoma [RCC], ovarian and endometrial) using Mendelian randomization (MR) methods. We used summary-level data from large genetic consortia for 114 530 cancer cases and 245 284 controls. We constructed genetic instruments using 18 genetic variants for adiponectin, 2 for leptin and 4 for both sOB-R and PAI-1 (P value for inclusion<5 x 10-8). Causal estimates were obtained using two-sample MR methods. In the inverse-variance weighted models, we found an inverse association between adiponectin and risk of colorectal cancer (odds ratio per 1 mug/mL increment in adiponectin concentration: 0.90 [95% confidence interval = 0.84-0.97]; P =.01); but, evidence of horizontal pleiotropy was detected and the association was not present when this was taken into consideration. No association was found for adiponectin and risks of pancreatic cancer, RCC, ovarian cancer and endometrial cancer. Leptin, sOB-R and PAI-1 were also similarly unrelated to risk of obesity-related cancers. Despite the large sample size, our MR analyses do not support causal effects of circulating adiponectin, leptin, sOB-R and PAI-1 concentrations on the development of five obesity-related cancers.Copyright © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.
- Published
- 2021
27. Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study.
- Author
-
Giles G.G., Tjonneland A., Masala G., Milne R.L., Zeegers M.P., Yu E.Y.-W., Wesselius A., Mehrkanoon S., Goosens M., Brinkman M., van den Brandt P., Grant E.J., White E., Weiderpass E., Le Calvez-Kelm F., Gunter M.J., Huybrechts I., Riboli E., Giles G.G., Tjonneland A., Masala G., Milne R.L., Zeegers M.P., Yu E.Y.-W., Wesselius A., Mehrkanoon S., Goosens M., Brinkman M., van den Brandt P., Grant E.J., White E., Weiderpass E., Le Calvez-Kelm F., Gunter M.J., Huybrechts I., and Riboli E.
- Abstract
Background: Although a potential inverse association between vegetable intake and bladder cancer risk has been reported, epidemiological evidence is inconsistent. This research aimed to elucidate the association between vegetable intake and bladder cancer risk by conducting a pooled analysis of data from prospective cohort studies. Method(s): Vegetable intake in relation to bladder cancer risk was examined by pooling individual-level data from 13 cohort studies, comprising 3203 cases among a total of 555,685 participants. Pooled multivariate hazard ratios (HRs), with corresponding 95% confidence intervals (CIs), were estimated using Cox proportional hazards regression models stratified by cohort for intakes of total vegetable, vegetable subtypes (i.e. non-starchy, starchy, green leafy and cruciferous vegetables) and individual vegetable types. In addition, a diet diversity score was used to assess the association of the varied types of vegetable intake on bladder cancer risk. Result(s): The association between vegetable intake and bladder cancer risk differed by sex (P-interaction = 0.011) and smoking status (P-interaction = 0.038); therefore, analyses were stratified by sex and smoking status. With adjustment of age, sex, smoking, energy intake, ethnicity and other potential dietary factors, we found that higher intake of total and non-starchy vegetables were inversely associated with the risk of bladder cancer among women (comparing the highest with lowest intake tertile: HR = 0.79, 95% CI = 0.64-0.98, P = 0.037 for trend, HR per 1 SD increment = 0.89, 95% CI = 0.81-0.99; HR = 0.78, 95% CI = 0.63-0.97, P = 0.034 for trend, HR per 1 SD increment = 0.88, 95% CI = 0.79-0.98, respectively). However, no evidence of association was observed among men, and the intake of vegetable was not found to be associated with bladder cancer when stratified by smoking status. Moreover, we found no evidence of association for diet diversity with bladder cancer risk. Conclusion(s): Hi
- Published
- 2021
28. Genetically predicted circulating c-reactive protein concentration and colorectal cancer survival: A mendelian randomization consortium study.
- Author
-
Hua X., Dai J.Y., Lindstrom S., Harrison T.A., Lin Y., Alberts S.R., Alwers E., Berndt S.I., Brenner H., Buchanan D.D., Campbell P.T., Casey G., Chang-Claude J., Gallinger S., Giles G.G., Goldberg R.M., Gunter M.J., Hoffmeister M., Jenkins M.A., Joshi A.D., Ma W., Milne R.L., Murphy N., Pai R.K., Sakoda L.C., Schoen R.E., Shi Q., Slattery M.L., Song M., White E., Le Marchand L., Chan A.T., Peters U., Newcomb P.A., Hua X., Dai J.Y., Lindstrom S., Harrison T.A., Lin Y., Alberts S.R., Alwers E., Berndt S.I., Brenner H., Buchanan D.D., Campbell P.T., Casey G., Chang-Claude J., Gallinger S., Giles G.G., Goldberg R.M., Gunter M.J., Hoffmeister M., Jenkins M.A., Joshi A.D., Ma W., Milne R.L., Murphy N., Pai R.K., Sakoda L.C., Schoen R.E., Shi Q., Slattery M.L., Song M., White E., Le Marchand L., Chan A.T., Peters U., and Newcomb P.A.
- Abstract
Background: A positive association between circulating Creactive protein (CRP) and colorectal cancer survival was reported in observational studies, which are susceptible to unmeasured confounding and reverse causality.Weused a Mendelian randomization approach to evaluate the association between genetically predicted CRP concentrations and colorectal cancer-specific survival. Method(s): We used individual-level data for 16,918 eligible colorectal cancer cases of European ancestry from 15 studies within the International Survival Analysis of Colorectal Cancer Consortium. Wecalculated a genetic-risk score based on 52 CRP-associated genetic variants identified from genome-wide association studies. Because of the non-collapsibility of hazard ratios from Cox proportional hazards models, we used the additive hazards model to calculate hazard differences (HD) and 95% confidence intervals (CI) for the association between genetically predicted CRP concentrations and colorectal cancer-specific survival, overall and by stage at diagnosis and tumor location. Analyses were adjusted for age at diagnosis, sex, body mass index, genotyping platform, study, and principal components. Result(s): Of the 5,395 (32%) deaths accrued over up to 10 years of follow-up, 3,808 (23%) were due to colorectal cancer. Genetically predicted CRP concentration was not associated with colorectal cancer-specific survival (HD, 1.15; 95% CI, 2.76 to 0.47 per 100,000 person-years; P = 0.16). Similarly, no associations were observed in subgroup analyses by stage at diagnosis or tumor location. Conclusion(s): Despite adequate power to detect moderate associations, our results did not support a causal effect of circulating CRP concentrations on colorectal cancer-specific survival.Copyright © 2021 American Association for Cancer Research Inc.. All rights reserved.
- Published
- 2021
29. Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies.
- Author
-
Jayasekara H., MacInnis R.J., Lujan-Barroso L., Mayen-Chacon A.-L., Cross A.J., Wallner B., Palli D., Ricceri F., Pala V., Panico S., Tumino R., Kuhn T., Kaaks R., Tsilidis K., Sanchez M.-J., Amiano P., Ardanaz E., Chirlaque Lopez M.D., Merino S., Rothwell J.A., Boutron-Ruault M.-C., Severi G., Sternby H., Sonestedt E., Bueno-de-Mesquita B., Boeing H., Travis R., Sandanger T.M., Trichopoulou A., Karakatsani A., Peppa E., Tjonneland A., Yang Y., Hodge A.M., Mitchell H., Haydon A., Room R., Hopper J.L., Weiderpass E., Gunter M.J., Riboli E., Giles G.G., Milne R.L., Agudo A., English D.R., Ferrari P., Jayasekara H., MacInnis R.J., Lujan-Barroso L., Mayen-Chacon A.-L., Cross A.J., Wallner B., Palli D., Ricceri F., Pala V., Panico S., Tumino R., Kuhn T., Kaaks R., Tsilidis K., Sanchez M.-J., Amiano P., Ardanaz E., Chirlaque Lopez M.D., Merino S., Rothwell J.A., Boutron-Ruault M.-C., Severi G., Sternby H., Sonestedt E., Bueno-de-Mesquita B., Boeing H., Travis R., Sandanger T.M., Trichopoulou A., Karakatsani A., Peppa E., Tjonneland A., Yang Y., Hodge A.M., Mitchell H., Haydon A., Room R., Hopper J.L., Weiderpass E., Gunter M.J., Riboli E., Giles G.G., Milne R.L., Agudo A., English D.R., and Ferrari P.
- Abstract
Alcohol consumption is causally linked to several cancers but the evidence for stomach cancer is inconclusive. In our study, the association between long-term alcohol intake and risk of stomach cancer and its subtypes was evaluated. We performed a pooled analysis of data collected at baseline from 491 714 participants in the European Prospective Investigation into Cancer and Nutrition and the Melbourne Collaborative Cohort Study. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for incident stomach cancer in relation to lifetime alcohol intake and group-based life course intake trajectories, adjusted for potential confounders including Helicobacter pylori infection. In all, 1225 incident stomach cancers (78% noncardia) were diagnosed over 7 094 637 person-years; 984 in 382 957 study participants with lifetime alcohol intake data (5 455 507 person-years). Although lifetime alcohol intake was not associated with overall stomach cancer risk, we observed a weak positive association with noncardia cancer (HR = 1.03, 95% CI: 1.00-1.06 per 10 g/d increment), with a HR of 1.50 (95% CI: 1.08-2.09) for >=60 g/d compared to 0.1 to 4.9 g/d. A weak inverse association with cardia cancer (HR = 0.93, 95% CI: 0.87-1.00) was also observed. HRs of 1.48 (95% CI: 1.10-1.99) for noncardia and 0.51 (95% CI: 0.26-1.03) for cardia cancer were observed for a life course trajectory characterized by heavy decreasing intake compared to light stable intake (Phomogeneity =.02). These associations did not differ appreciably by smoking or H pylori infection status. Limiting alcohol use during lifetime, particularly avoiding heavy use during early adulthood, might help prevent noncardia stomach cancer. Heterogeneous associations observed for cardia and noncardia cancers may indicate etiologic differences.Copyright © 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
- Published
- 2021
30. Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study.
- Author
-
Hampe J., Zuber V., Cross A.J., Perez-Cornago A., Hunter D.J., van Duijnhoven F.J.B., Albanes D., Arndt V., Berndt S.I., Bezieau S., Bishop D.T., Boehm J., Brenner H., Burnett-Hartman A., Campbell P.T., Casey G., Castellvi-Bel S., Chan A.T., Chang-Claude J., de la Chapelle A., Figueiredo J.C., Gallinger S.J., Giles G.G., Goodman P.J., Gsur A., Markozannes G., Hampel H., Hoffmeister M., Jenkins M.A., Keku T.O., Kweon S.-S., Larsson S.C., Le Marchand L., Li C.I., Li L., Lindblom A., Martin V., Milne R.L., Moreno V., Nan H., Nassir R., Newcomb P.A., Offit K., Pharoah P.D.P., Platz E.A., Potter J.D., Qi L., Rennert G., Sakoda L.C., Schafmayer C., Slattery M.L., Snetselaar L., Schenk J., Thibodeau S.N., Ulrich C.M., Van Guelpen B., Harlid S., Visvanathan K., Vodickova L., Wang H., White E., Wolk A., Woods M.O., Wu A.H., Zheng W., Bueno-de-Mesquita B., Boutron-Ruault M.-C., Hughes D.J., Jakszyn P., Kuhn T., Palli D., Riboli E., Giovannucci E.L., Banbury B.L., Gruber S.B., Peters U., Gunter M.J., Tsilidis K.K., Papadimitriou N., Dimou N., Gill D., Lewis S.J., Martin R.M., Murphy N., Burrows K., Lopez D.S., Key T.J., Travis R.C., Hampe J., Zuber V., Cross A.J., Perez-Cornago A., Hunter D.J., van Duijnhoven F.J.B., Albanes D., Arndt V., Berndt S.I., Bezieau S., Bishop D.T., Boehm J., Brenner H., Burnett-Hartman A., Campbell P.T., Casey G., Castellvi-Bel S., Chan A.T., Chang-Claude J., de la Chapelle A., Figueiredo J.C., Gallinger S.J., Giles G.G., Goodman P.J., Gsur A., Markozannes G., Hampel H., Hoffmeister M., Jenkins M.A., Keku T.O., Kweon S.-S., Larsson S.C., Le Marchand L., Li C.I., Li L., Lindblom A., Martin V., Milne R.L., Moreno V., Nan H., Nassir R., Newcomb P.A., Offit K., Pharoah P.D.P., Platz E.A., Potter J.D., Qi L., Rennert G., Sakoda L.C., Schafmayer C., Slattery M.L., Snetselaar L., Schenk J., Thibodeau S.N., Ulrich C.M., Van Guelpen B., Harlid S., Visvanathan K., Vodickova L., Wang H., White E., Wolk A., Woods M.O., Wu A.H., Zheng W., Bueno-de-Mesquita B., Boutron-Ruault M.-C., Hughes D.J., Jakszyn P., Kuhn T., Palli D., Riboli E., Giovannucci E.L., Banbury B.L., Gruber S.B., Peters U., Gunter M.J., Tsilidis K.K., Papadimitriou N., Dimou N., Gill D., Lewis S.J., Martin R.M., Murphy N., Burrows K., Lopez D.S., Key T.J., and Travis R.C.
- Abstract
BACKGROUND: The literature on associations of circulating concentrations of minerals and vitamins with risk of colorectal cancer is limited and inconsistent. Evidence from randomized controlled trials (RCTs) to support the efficacy of dietary modification or nutrient supplementation for colorectal cancer prevention is also limited. OBJECTIVE(S): To complement observational and RCT findings, we investigated associations of genetically predicted concentrations of 11 micronutrients (beta-carotene, calcium, copper, folate, iron, magnesium, phosphorus, selenium, vitamin B-6, vitamin B-12, and zinc) with colorectal cancer risk using Mendelian randomization (MR). METHOD(S): Two-sample MR was conducted using 58,221 individuals with colorectal cancer and 67,694 controls from the Genetics and Epidemiology of Colorectal Cancer Consortium, Colorectal Cancer Transdisciplinary Study, and Colon Cancer Family Registry. Inverse variance-weighted MR analyses were performed with sensitivity analyses to assess the impact of potential violations of MR assumptions. RESULT(S): Nominally significant associations were noted for genetically predicted iron concentration and higher risk of colon cancer [ORs per SD (ORSD): 1.08; 95% CI: 1.00, 1.17; P value=0.05] and similarly for proximal colon cancer, and for vitamin B-12 concentration and higher risk of colorectal cancer (ORSD: 1.12; 95% CI: 1.03, 1.21; P value=0.01) and similarly for colon cancer. A nominally significant association was also noted for genetically predicted selenium concentration and lower risk of colon cancer (ORSD: 0.98; 95% CI: 0.96, 1.00; P value=0.05) and similarly for distal colon cancer. These associations were robust to sensitivity analyses. Nominally significant inverse associations were observed for zinc and risk of colorectal and distal colon cancers, but sensitivity analyses could not be performed. None of these findings survived correction for multiple testing. Genetically predicted concentrations of beta-caroten
- Published
- 2021
31. Salicylic acid and risk of colorectal cancer: A two-sample mendelian randomization study.
- Author
-
Nounu A., Richmond R.C., Stewart I.D., Surendran P., Wareham N.J., Butterworth A., Weinstein S.J., Albanes D., Baron J.A., Hopper J.L., Figueiredo J.C., Newcomb P.A., Lindor N.M., Casey G., Platz E.A., Marchand L.L., Ulrich C.M., Li C.I., van Dujinhoven F.J.B., Gsur A., Campbell P.T., Moreno V., Vodicka P., Vodickova L., Amitay E., Alwers E., Chang-Claude J., Sakoda L.C., Slattery M.L., Schoen R.E., Gunter M.J., Castellvi-Bel S., Kim H.-R., Kweon S.-S., Chan A.T., Li L., Zheng W., Bishop D.T., Buchanan D.D., Giles G.G., Gruber S.B., Rennert G., Stadler Z.K., Harrison T.A., Lin Y., Keku T.O., Woods M.O., Schafmayer C., Van Guelpen B., Gallinger S., Hampel H., Berndt S.I., Pharoah P.D.P., Lindblom A., Wolk A., Wu A.H., White E., Peters U., Drew D.A., Scherer D., Bermejo J.L., Brenner H., Hoffmeister M., Williams A.C., Relton C.L., Nounu A., Richmond R.C., Stewart I.D., Surendran P., Wareham N.J., Butterworth A., Weinstein S.J., Albanes D., Baron J.A., Hopper J.L., Figueiredo J.C., Newcomb P.A., Lindor N.M., Casey G., Platz E.A., Marchand L.L., Ulrich C.M., Li C.I., van Dujinhoven F.J.B., Gsur A., Campbell P.T., Moreno V., Vodicka P., Vodickova L., Amitay E., Alwers E., Chang-Claude J., Sakoda L.C., Slattery M.L., Schoen R.E., Gunter M.J., Castellvi-Bel S., Kim H.-R., Kweon S.-S., Chan A.T., Li L., Zheng W., Bishop D.T., Buchanan D.D., Giles G.G., Gruber S.B., Rennert G., Stadler Z.K., Harrison T.A., Lin Y., Keku T.O., Woods M.O., Schafmayer C., Van Guelpen B., Gallinger S., Hampel H., Berndt S.I., Pharoah P.D.P., Lindblom A., Wolk A., Wu A.H., White E., Peters U., Drew D.A., Scherer D., Bermejo J.L., Brenner H., Hoffmeister M., Williams A.C., and Relton C.L.
- Abstract
Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes; (2) pathway SNPs present in enzymes' coding regions; and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR:1.03, 95% CI: 0.84-1.27 and OR: 1.08, 95% CI:0.86-1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.Copyright © 2021 by the authors. Li-censee MDPI, Basel, Switzerland.
- Published
- 2021
32. Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: A Mendelian randomization study.
- Author
-
Tsilidis K.K., Papadimitriou N., Dimou N., Gill D., Lewis S.J., Martin R.M., Murphy N., Markozannes G., Zuber V., Cross A.J., Burrows K., Lopez D.S., Key T.J., Travis R.C., Perez-Cornago A., Hunter D.J., Van Duijnhoven F.J.B., Albanes D., Arndt V., Berndt S.I., Bezieau S., Bishop D.T., Boehm J., Brenner H., Burnett-Hartman A., Campbell P.T., Casey G., Castellvi-Bel S., Chan A.T., Chang-Claude J., De La Chapelle A., Figueiredo J.C., Gallinger S.J., Giles G.G., Goodman P.J., Gsur A., Hampe J., Hampel H., Hoffmeister M., Jenkins M.A., Keku T.O., Kweon S.-S., Larsson S.C., Le Marchand L., Li C.I., Li L., Lindblom A., Martin V., Milne R.L., Moreno V., Nan H., Nassir R., Newcomb P.A., Offit K., Pharoah P.D.P., Platz E.A., Potter J.D., Qi L., Rennert G., Sakoda L.C., Schafmayer C., Slattery M.L., Snetselaar L., Schenk J., Thibodeau S.N., Ulrich C.M., Van Guelpen B., Harlid S., Visvanathan K., Vodickova L., Wang H., White E., Wolk A., Woods M.O., Wu A.H., Zheng W., Bueno-De-Mesquita B., Boutron-Ruault M.-C., Hughes D.J., Jakszyn P., Kuhn T., Palli D., Riboli E., Giovannucci E.L., Banbury B.L., Gruber S.B., Peters U., Gunter M.J., Tsilidis K.K., Papadimitriou N., Dimou N., Gill D., Lewis S.J., Martin R.M., Murphy N., Markozannes G., Zuber V., Cross A.J., Burrows K., Lopez D.S., Key T.J., Travis R.C., Perez-Cornago A., Hunter D.J., Van Duijnhoven F.J.B., Albanes D., Arndt V., Berndt S.I., Bezieau S., Bishop D.T., Boehm J., Brenner H., Burnett-Hartman A., Campbell P.T., Casey G., Castellvi-Bel S., Chan A.T., Chang-Claude J., De La Chapelle A., Figueiredo J.C., Gallinger S.J., Giles G.G., Goodman P.J., Gsur A., Hampe J., Hampel H., Hoffmeister M., Jenkins M.A., Keku T.O., Kweon S.-S., Larsson S.C., Le Marchand L., Li C.I., Li L., Lindblom A., Martin V., Milne R.L., Moreno V., Nan H., Nassir R., Newcomb P.A., Offit K., Pharoah P.D.P., Platz E.A., Potter J.D., Qi L., Rennert G., Sakoda L.C., Schafmayer C., Slattery M.L., Snetselaar L., Schenk J., Thibodeau S.N., Ulrich C.M., Van Guelpen B., Harlid S., Visvanathan K., Vodickova L., Wang H., White E., Wolk A., Woods M.O., Wu A.H., Zheng W., Bueno-De-Mesquita B., Boutron-Ruault M.-C., Hughes D.J., Jakszyn P., Kuhn T., Palli D., Riboli E., Giovannucci E.L., Banbury B.L., Gruber S.B., Peters U., and Gunter M.J.
- Abstract
Background: The literature on associations of circulating concentrations of minerals and vitamins with risk of colorectal cancer is limited and inconsistent. Evidence from randomized controlled trials (RCTs) to support the efficacy of dietary modification or nutrient supplementation for colorectal cancer prevention is also limited. Objective(s): To complement observational and RCT findings, we investigated associations of genetically predicted concentrations of 11 micronutrients (beta-carotene, calcium, copper, folate, iron, magnesium, phosphorus, selenium, vitamin B-6, vitamin B-12, and zinc) with colorectal cancer risk using Mendelian randomization (MR). Method(s): Two-sample MR was conducted using 58,221 individuals with colorectal cancer and 67,694 controls from the Genetics and Epidemiology of Colorectal Cancer Consortium, Colorectal Cancer Transdisciplinary Study, and Colon Cancer Family Registry. Inverse variance-weighted MR analyses were performed with sensitivity analyses to assess the impact of potential violations of MR assumptions. Result(s): Nominally significant associations were noted for genetically predicted iron concentration and higher risk of colon cancer [ORs per SD (ORSD): 1.08 95% CI: 1.00, 1.17 P value = 0.05] and similarly for proximal colon cancer, and for vitamin B-12 concentration and higher risk of colorectal cancer (ORSD: 1.12 95% CI: 1.03, 1.21 P value = 0.01) and similarly for colon cancer. A nominally significant association was also noted for genetically predicted selenium concentration and lower risk of colon cancer (ORSD: 0.98 95% CI: 0.96, 1.00 P value = 0.05) and similarly for distal colon cancer. These associations were robust to sensitivity analyses. Nominally significant inverse associations were observed for zinc and risk of colorectal and distal colon cancers, but sensitivity analyses could not be performed. None of these findings survived correction for multiple testing. Genetically predicted concentrations of beta-caroten
- Published
- 2021
33. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes and tumor location.
- Author
-
Labadie J.D., Harrison T.A., Banbury B., Amtay E.L., Bernd S., Brenner H., Buchanan D.D., Campbell P.T., Cao Y., Chan A.T., Chang-Claude J., Englishc D., Figueiredo J.C., Gallingerc S.J., Gilesc G.G., Gunter M.J., Hoffmeisterc M., Hsu L., Jenkins M.A., Lin Y., Milnec R.L., Moreno V., Murphyc N., Ogino S., Phipps A.I., Sakoda L.C., Slattery M.L., Southey M.C., Sun W., Thibodeau S.N., Van Guelpen B., Zaidi S.H., Peters U., Newcomb P.A., Labadie J.D., Harrison T.A., Banbury B., Amtay E.L., Bernd S., Brenner H., Buchanan D.D., Campbell P.T., Cao Y., Chan A.T., Chang-Claude J., Englishc D., Figueiredo J.C., Gallingerc S.J., Gilesc G.G., Gunter M.J., Hoffmeisterc M., Hsu L., Jenkins M.A., Lin Y., Milnec R.L., Moreno V., Murphyc N., Ogino S., Phipps A.I., Sakoda L.C., Slattery M.L., Southey M.C., Sun W., Thibodeau S.N., Van Guelpen B., Zaidi S.H., Peters U., and Newcomb P.A.
- Abstract
Background: Postmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor location. Method(s): We pooled data on tumor subtypes (microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, pathway: Adenoma-carcinoma, alternate, serrated), tumor location (proximal colon, distal colon, rectum), and HT use among 8220 postmenopausal women (3898 CRC cases and 4322 controls) from 8 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CIs) for the association of ever vs never HT use with each tumor subtype compared with controls. Models were adjusted for study, age, body mass index, smoking status, and CRC family history. All statistical tests were 2- sided. Result(s): Among postmenopausal women, ever HT use was associated with a 38% reduction in overall CRC risk (OR =0.62, 95% CI = 0.56 to 0.69). This association was similar according to microsatellite instability, CpG island methylator phenotype and BRAF or KRAS status. However, the association was attenuated for tumors arising through the serrated pathway (OR = 0.81, 95% CI = 0.66 to 1.01) compared with the adenoma-carcinoma pathway (OR = 0.63, 95% CI = 0.55 to 0.73; Phet =.04) and alternate pathway (OR = 0.61, 95% CI = 0.51 to 0.72). Additionally, proximal colon tumors had a weaker association (OR = 0.71, 95% CI = 0.62 to 0.80) compared with rectal (OR = 0.54, 95% CI = 0.46 to 0.63) and distal colon (OR = 0.57, 95% CI = 0.49 to 0.66; Phet =.01) tumors. Conclusion(s): We observed a strong inverse association between HT use and overall CRC risk, which may predominantly reflect a benefit of HT use for tumors arising through the adenoma-carcinoma and alternate pathways as well as distal colon and rectal tumors.Copy
- Published
- 2021
34. A combined proteomics and mendelian randomization approach to investigate the effects of aspirin-targeted proteins on colorectal cancer.
- Author
-
Pharoah P.D.P., Nounu A., Greenhough A., Heesom K.J., Richmond R.C., Zheng J., Weinstein S.J., Albanes D., Gallinger S., Hampel H., Berndt S.I., Lindblom A., Wolk A., Wu A.H., White E., Peters U., Drew D.A., Scherer D., Bermejo J.L., Williams A.C., Relton C.L., Baron J.A., Hopper J.L., Figueiredo J.C., Newcomb P.A., Lindor N.M., Casey G., Platz E.A., Le Marchand L., Ulrich C.M., Li C.I., van Duijnhoven F.J.B., Gsur A., Campbell P.T., Moreno V., Vodicka P., Vodickova L., Brenner H., Chang-Claude J., Hoffmeister M., Sakoda L.C., Slattery M.L., Schoen R.E., Gunter M.J., Castellvi-Bel S., Kim H.R., Kweon S.-S., Chan A.T., Li L., Zheng W., Bishop D.T., Buchanan D.D., Giles G.G., Gruber S.B., Rennert G., Stadler Z.K., Harrison T.A., Lin Y., Keku T.O., Woods M.O., Schafmayer C., van Guelpen B., Pharoah P.D.P., Nounu A., Greenhough A., Heesom K.J., Richmond R.C., Zheng J., Weinstein S.J., Albanes D., Gallinger S., Hampel H., Berndt S.I., Lindblom A., Wolk A., Wu A.H., White E., Peters U., Drew D.A., Scherer D., Bermejo J.L., Williams A.C., Relton C.L., Baron J.A., Hopper J.L., Figueiredo J.C., Newcomb P.A., Lindor N.M., Casey G., Platz E.A., Le Marchand L., Ulrich C.M., Li C.I., van Duijnhoven F.J.B., Gsur A., Campbell P.T., Moreno V., Vodicka P., Vodickova L., Brenner H., Chang-Claude J., Hoffmeister M., Sakoda L.C., Slattery M.L., Schoen R.E., Gunter M.J., Castellvi-Bel S., Kim H.R., Kweon S.-S., Chan A.T., Li L., Zheng W., Bishop D.T., Buchanan D.D., Giles G.G., Gruber S.B., Rennert G., Stadler Z.K., Harrison T.A., Lin Y., Keku T.O., Woods M.O., Schafmayer C., and van Guelpen B.
- Abstract
Background: Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk. Method(s): Human colorectal adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope labeling with amino acids in cell culture (SILAC) based proteomics approach identified altered protein expression. Protein quantitative trait loci (pQTLs) from INTERVAL (N 1/4 3,301) and expression QTLs (eQTLs) from the eQTLGen Consortium (N 1/4 31,684) were used as genetic proxies for protein and mRNA expression levels. Two-sample MR of mRNA/protein expression on CRC risk was performed using eQTL/pQTL data combined with CRC genetic summary data from the Colon Cancer Family Registry (CCFR), Colorectal Transdisciplinary (CORECT), Genetics and Epidemiology of Colorectal Cancer (GECCO) consortia and UK Biobank (55,168 cases and 65,160 controls). Result(s): Altered expression was detected for 125/5886 proteins. Of these, aspirin decreased MCM6, RRM2, and ARFIP2 expression, and MR analysis showed that a standard deviation increase in mRNA/protein expression was associated with increased CRC risk (OR: 1.08, 95% CI, 1.03-1.13; OR: 3.33, 95% CI, 2.46-4.50; and OR: 1.15, 95% CI, 1.02-1.29, respectively). Conclusion(s): MCM6 and RRM2 are involved in DNA repair whereby reduced expression may lead to increased DNA aberrations and ultimately cancer cell death, whereas ARFIP2 is involved in actin cytoskeletal regulation, indicating a possible role in aspirin's reduction of metastasis. Impact: Our approach has shown how laboratory experiments and population-based approaches can combine to identify aspirin-targeted proteins possibly affecting CRC risk.Copyright ©2020 American Association for Cancer Research.
- Published
- 2021
35. The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium.
- Author
-
Guida F., Tan V.Y., Corbin L.J., Smith-Byrne K., Alcala K., Langenberg C., Stewart I.D., Butterworth A.S., Surendran P., Achaintre D., Adamski J., Exezarreta P.A., Bergmann M.M., Bull C.J., Dahm C.C., Gicquiau A., Giles G.G., Gunter M.J., Haller T., Langhammer A., Larose T.L., Ljungberg B., Metspalu A., Milne R.L., Muller D.C., Nost T.H., Sorgjerd E.P., Prehn C., Riboli E., Rinaldi S., Rothwell J.A., Scalbert A., Schmidt J.A., Severi G., Sieri S., Vermeulen R., Vincent E.E., Waldenberger M., Timpson N.J., Johansson M., Guida F., Tan V.Y., Corbin L.J., Smith-Byrne K., Alcala K., Langenberg C., Stewart I.D., Butterworth A.S., Surendran P., Achaintre D., Adamski J., Exezarreta P.A., Bergmann M.M., Bull C.J., Dahm C.C., Gicquiau A., Giles G.G., Gunter M.J., Haller T., Langhammer A., Larose T.L., Ljungberg B., Metspalu A., Milne R.L., Muller D.C., Nost T.H., Sorgjerd E.P., Prehn C., Riboli E., Rinaldi S., Rothwell J.A., Scalbert A., Schmidt J.A., Severi G., Sieri S., Vermeulen R., Vincent E.E., Waldenberger M., Timpson N.J., and Johansson M.
- Abstract
Background Excess bodyweight and related metabolic perturbations have : been implicated in kidney cancer aetiology, but the specific molecular mechanisms underlying these relationships are poorly understood. In this study, we sought to identify circulating metabolites that predispose kidney cancer and to evaluate the extent to which they are influenced by body mass index (BMI). Methods and findings We assessed the association between circulating levels of 1,416 metabolites and incident kidney cancer using pre-diagnostic blood samples from up to 1,305 kidney cancer case-control pairs from 5 prospective cohort studies. Cases were diagnosed on average 8 years after blood collection. We found 25 metabolites robustly associated with kidney cancer risk. In particular, 14 glycerophospholipids (GPLs) were inversely associated with risk, including 8 phosphatidylcholines (PCs) and 2 plasmalogens. The PC with the strongest association was PC ae C34:3 with an odds ratio (OR) for 1 standard deviation (SD) increment of 0.75 (95% confidence interval [CI]: 0.68 to 0.83, p = 2.6 x 10-8). In contrast, 4 amino acids, including glutamate (OR for 1 SD = 1.39, 95% CI: 1.20 to 1.60, p = 1.6 x 10-5), were positively associated with risk. Adjusting for BMI partly attenuated the risk association for some -but not all-metabolites, whereas other known risk factors of kidney cancer, such as smoking and alcohol consumption, had minimal impact on the observed associations. A mendelian randomisation (MR) analysis of the influence of BMI on the blood metabolome highlighted that some metabolites associated with kidney cancer risk are influenced by BMI. Specifically, elevated BMI appeared to decrease levels of several GPLs that were also found inversely associated with kidney cancer risk (e.g., -0.17 SD change [sBMI] in 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) levels per SD change in BMI, p = 3.4 x 10-5). BMI was also associated with increased levels of glutamate (sBMI: 0.12, p = 1.5 x 10-3
- Published
- 2021
36. Red blood cell fatty acids and risk of colorectal cancer in the European Prospective investigation into cancer and nutrition (EPIC)
- Author
-
IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Linseisen, J., Grundmann, N., Zoller, D., Kuhn, T., Chajes, V., Fedirko, V., Weiderpass, E., Dahm, C.C., Overvad, K., Tjønneland, A., Boutron-Ruault, M.-C., Rothwell, J.A., Severi, G., Kaaks, R., Schulze, M.B., Aleksandrova, K., Sieri, S., Panico, S., Tumino, R., Masala, G., de Marco, L., Bueno-De-Mesquita, B., Vermeulen, R., Gram, I.T., Skeie, G., Chirlaque, M.-D., Ardanaz, E., Agudo, A., Sánchez, M.-J., Amiano, P., Wennberg, M., Bodén, S., Perez-Cornago, A., Aglago, E.K., Gunter, M.J., Jenab, M., Heath, A.K., Nieters, A., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Linseisen, J., Grundmann, N., Zoller, D., Kuhn, T., Chajes, V., Fedirko, V., Weiderpass, E., Dahm, C.C., Overvad, K., Tjønneland, A., Boutron-Ruault, M.-C., Rothwell, J.A., Severi, G., Kaaks, R., Schulze, M.B., Aleksandrova, K., Sieri, S., Panico, S., Tumino, R., Masala, G., de Marco, L., Bueno-De-Mesquita, B., Vermeulen, R., Gram, I.T., Skeie, G., Chirlaque, M.-D., Ardanaz, E., Agudo, A., Sánchez, M.-J., Amiano, P., Wennberg, M., Bodén, S., Perez-Cornago, A., Aglago, E.K., Gunter, M.J., Jenab, M., Heath, A.K., and Nieters, A.
- Published
- 2021
37. A New Pipeline for the Normalization and Pooling of Metabolomics Data
- Author
-
IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Sub Inorganic Chemistry and Catalysis, Viallon, V., His, M., Rinaldi, S., Breeur, M., Gicquiau, A., Hemon, B., Overvad, K., Tjønneland, A., Rostgaard-Hansen, A.L., Rothwell, J.A., Lecuyer, L., Severi, G., Kaaks, R., Johnson, T., Schulze, M.B., Palli, D., Agnoli, C., Panico, S., Tumino, R., Ricceri, F., Monique Verschuren, W.M., Engelfriet, P., Onland-Moret, C., Vermeulen, R., Nøst, T.H., Urbarova, I., Zamora-Ros, R., Rodriguez-Barranco, M., Amiano, P., Huerta, J.M., Ardanaz, E., Melander, O., Ottoson, F., Vidman, L., Rentoft, M., Schmidt, J.A., Travis, R.C., Weiderpass, E., Johansson, M., Dossus, L., Jenab, M., Gunter, M.J., Bermejo, J.L., Scherer, D., Salek, R.M., Keski-Rahkonen, P., Ferrari, P., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Sub Inorganic Chemistry and Catalysis, Viallon, V., His, M., Rinaldi, S., Breeur, M., Gicquiau, A., Hemon, B., Overvad, K., Tjønneland, A., Rostgaard-Hansen, A.L., Rothwell, J.A., Lecuyer, L., Severi, G., Kaaks, R., Johnson, T., Schulze, M.B., Palli, D., Agnoli, C., Panico, S., Tumino, R., Ricceri, F., Monique Verschuren, W.M., Engelfriet, P., Onland-Moret, C., Vermeulen, R., Nøst, T.H., Urbarova, I., Zamora-Ros, R., Rodriguez-Barranco, M., Amiano, P., Huerta, J.M., Ardanaz, E., Melander, O., Ottoson, F., Vidman, L., Rentoft, M., Schmidt, J.A., Travis, R.C., Weiderpass, E., Johansson, M., Dossus, L., Jenab, M., Gunter, M.J., Bermejo, J.L., Scherer, D., Salek, R.M., Keski-Rahkonen, P., and Ferrari, P.
- Published
- 2021
38. The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium
- Author
-
Afd. Theologie, Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Guida, F., Tan, V.Y., Corbin, L.J., Smith-Byrne, K., Alcala, K., Langenberg, C., Stewart, I.D., Butterworth, A.S., Surendran, P., Achaintre, D., Adamski, J., Exezarreta, P.A., Bergmann, M.M., Bull, C.J., Dahm, C.C., Gicquiau, A., Giles, G.G., Gunter, M.J., Haller, T., Langhammer, A., Larose, T.L., Ljungberg, B., Metspalu, A., Milne, R.L., Muller, D.C., Nøst, T.H., Sørgjerd, E.P., Prehn, C., Riboli, E., Rinaldi, S., Rothwell, J.A., Scalbert, A., Schmidt, J.A., Severi, G., Sieri, S., Vermeulen, R., Vincent, E.E., Waldenberger, M., Timpson, N.J., Johansson, M., Afd. Theologie, Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Guida, F., Tan, V.Y., Corbin, L.J., Smith-Byrne, K., Alcala, K., Langenberg, C., Stewart, I.D., Butterworth, A.S., Surendran, P., Achaintre, D., Adamski, J., Exezarreta, P.A., Bergmann, M.M., Bull, C.J., Dahm, C.C., Gicquiau, A., Giles, G.G., Gunter, M.J., Haller, T., Langhammer, A., Larose, T.L., Ljungberg, B., Metspalu, A., Milne, R.L., Muller, D.C., Nøst, T.H., Sørgjerd, E.P., Prehn, C., Riboli, E., Rinaldi, S., Rothwell, J.A., Scalbert, A., Schmidt, J.A., Severi, G., Sieri, S., Vermeulen, R., Vincent, E.E., Waldenberger, M., Timpson, N.J., and Johansson, M.
- Published
- 2021
39. Associations between dietary amino acid intakes and blood concentration levels
- Author
-
IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Iguacel, I., Perez-Cornago, A., Van Puyvelde, H., Travis, R., Stepien, M., Scalbert, A., Casagrande, C., Weiderpass, E., Riboli, E., Schulze, M.B., Skeie, G., Bodén, S., Boeing, H., Cross, A.J., Harlid, S., Jensen, T.E., Huerta, J.M., Katzke, V., Kühn, T., Lujan-Barroso, L., Masala, G., Rodriguez-Barranco, M., Rostgaard-Hansen, A.L., van der Schouw, Y.T., Vermeulen, R., Tagliabue, G., Tjønneland, A., Trevisan, M., Ferrari, P., Gunter, M.J., Huybrechts, I., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Iguacel, I., Perez-Cornago, A., Van Puyvelde, H., Travis, R., Stepien, M., Scalbert, A., Casagrande, C., Weiderpass, E., Riboli, E., Schulze, M.B., Skeie, G., Bodén, S., Boeing, H., Cross, A.J., Harlid, S., Jensen, T.E., Huerta, J.M., Katzke, V., Kühn, T., Lujan-Barroso, L., Masala, G., Rodriguez-Barranco, M., Rostgaard-Hansen, A.L., van der Schouw, Y.T., Vermeulen, R., Tagliabue, G., Tjønneland, A., Trevisan, M., Ferrari, P., Gunter, M.J., and Huybrechts, I.
- Published
- 2021
40. Prospective analysis of circulating metabolites and endometrial cancer risk
- Author
-
Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Dossus, L., Kouloura, E., Biessy, C., Viallon, V., Siskos, A.P., Dimou, N., Rinaldi, S., Merritt, M.A., Allen, N., Fortner, R., Kaaks, R., Weiderpass, E., Gram, I.T., Rothwell, J.A., Lécuyer, L., Severi, G., Schulze, M.B., Nøst, T.H., Crous-Bou, M., Sánchez, M.-J., Amiano, P., Colorado-Yohar, S.M., Gurrea, A.B., Schmidt, J.A., Palli, D., Agnoli, C., Tumino, R., Sacerdote, C., Mattiello, A., Vermeulen, R., Heath, A.K., Christakoudi, S., Tsilidis, K.K., Travis, R.C., Gunter, M.J., Keun, H.C., Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Dossus, L., Kouloura, E., Biessy, C., Viallon, V., Siskos, A.P., Dimou, N., Rinaldi, S., Merritt, M.A., Allen, N., Fortner, R., Kaaks, R., Weiderpass, E., Gram, I.T., Rothwell, J.A., Lécuyer, L., Severi, G., Schulze, M.B., Nøst, T.H., Crous-Bou, M., Sánchez, M.-J., Amiano, P., Colorado-Yohar, S.M., Gurrea, A.B., Schmidt, J.A., Palli, D., Agnoli, C., Tumino, R., Sacerdote, C., Mattiello, A., Vermeulen, R., Heath, A.K., Christakoudi, S., Tsilidis, K.K., Travis, R.C., Gunter, M.J., and Keun, H.C.
- Published
- 2021
41. Circulating tryptophan metabolites and risk of colon cancer: Results from case-control and prospective cohort studies
- Author
-
Papadimitriou, N., Papadimitriou, N., Gunter, M.J., Murphy, N., Gicquiau, A., Achaintre, D., Brezina, S., Gumpenberger, T., Baierl, A., Ose, J., Geijsen, A.J.M.R., van Roekel, E.H., Gsur, A., Gigic, B., Habermann, N., Ulrich, C.M., Kampman, E., Weijenberg, M.P., Ueland, P.M., Kaaks, R., Katzke, V., Krogh, V., Bueno-de-Mesquita, B., Ardanaz, E., Travis, R.C., Schulze, M.B., Sanchez, M.J., Colorado-Yohar, S.M., Weiderpass, E., Scalbert, A., Keski-Rahkonen, P., Papadimitriou, N., Papadimitriou, N., Gunter, M.J., Murphy, N., Gicquiau, A., Achaintre, D., Brezina, S., Gumpenberger, T., Baierl, A., Ose, J., Geijsen, A.J.M.R., van Roekel, E.H., Gsur, A., Gigic, B., Habermann, N., Ulrich, C.M., Kampman, E., Weijenberg, M.P., Ueland, P.M., Kaaks, R., Katzke, V., Krogh, V., Bueno-de-Mesquita, B., Ardanaz, E., Travis, R.C., Schulze, M.B., Sanchez, M.J., Colorado-Yohar, S.M., Weiderpass, E., Scalbert, A., and Keski-Rahkonen, P.
- Abstract
Dysregulation of tryptophan metabolism has been linked to colorectal tumorigenesis; however, epidemiological studies investigating tryptophan metabolites in relation to colorectal cancer risk are limited. We studied associations of plasma tryptophan, serotonin and kynurenine with colon cancer risk in two studies with cancer patients and controls, and in one prospective cohort: ColoCare Study (110 patients/153 controls), the Colorectal Cancer Study of Austria (CORSA; 46 patients/390 controls) and the European Prospective Investigation into Cancer and Nutrition (EPIC; 456 matched case-control pairs). Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for colon cancer risk. Tryptophan was inversely associated with colon cancer risk in ColoCare (OR per 1-SD = 0.44; 95% CI, 0.31-0.64) and EPIC (OR per 1-SD = 0.86; 95% CI, 0.74-0.99). Comparing detectable vs nondetectable levels, serotonin was positively associated with colon cancer in CORSA (OR = 6.39; 95% CI, 3.61-11.3) and EPIC (OR = 2.03; 95% CI, 1.20-3.40). Kynurenine was inversely associated with colon cancer in ColoCare (OR per 1-SD = 0.74; 95% CI, 0.55-0.98), positively associated in CORSA (OR per 1-SD = 1.79; 95% CI, 1.27-2.52), while no association was observed in EPIC. The kynurenine-to-tryptophan ratio was positively associated with colon cancer in ColoCare (OR per 1-SD = 1.38; 95% CI, 1.03-1.84) and CORSA (OR per 1-SD = 1.44; 95% CI, 1.06-1.96), but not in EPIC. These results suggest that higher plasma tryptophan may be associated with lower colon cancer risk, while increased serotonin may be associated with a higher risk of colon cancer. The kynurenine-to-tryptophan ratio may also reflect altered tryptophan catabolism during colon cancer development.
- Published
- 2021
42. A metabolomic study of red and processed meat intake and acylcarnitine concentrations in human urine and blood
- Author
-
Wedekind, R., Kiss, A., Keski-Rahkonen, P., Viallon, V., Rothwell, J.A., Cross, A.J., Rostgaard-Hansen, A.L., Sandanger, T.M., Jakszyn, P., Pala, V., Vermeulen, R., Schulze, M.B., Kühn, T., Johnson, T., Trichopoulou, A., Peppa, E., Vechia, C.L., Masala, G., Tumino, R., Sacerdote, C., Wittenbecher, C., de Magistris, M.S., Dahm, C.C., Severi, G., Mancini, F.R., Weiderpass, E., Gunter, M.J., Huybrechts, I., Scalbert, A., IRAS OH Epidemiology Chemical Agents, and dIRAS RA-2
- Subjects
acylcarnitines ,blood ,meat intake ,red and processed meat ,metabolomics ,urine - Abstract
Background Acylcarnitines (ACs) play a major role in fatty acid metabolism and are potential markers of metabolic dysfunction with higher blood concentrations reported in obese and diabetic individuals. Diet, and in particular red and processed meat intake, has been shown to influence AC concentrations but data on the effect of meat consumption on AC concentrations is limited. Objectives To investigate the effect of red and processed meat intake on AC concentrations in plasma and urine using a randomized controlled trial with replication in an observational cohort. Methods In the randomized crossover trial, 12 volunteers successively consumed 2 different diets containing either pork or tofu for 3 d each. A panel of 44 ACs including several oxidized ACs was analyzed by LC-MS in plasma and urine samples collected after the 3-d period. ACs that were associated with pork intake were then measured in urine (n = 474) and serum samples (n = 451) from the European Prospective Investigation into Cancer and nutrition (EPIC) study and tested for associations with habitual red and processed meat intake derived from dietary questionnaires. Results In urine samples from the intervention study, pork intake was positively associated with concentrations of 18 short- and medium-chain ACs. Eleven of these were also positively associated with habitual red and processed meat intake in the EPIC cross-sectional study. In blood, C18:0 was positively associated with red meat intake in both the intervention study (q = 0.004, Student's t-test) and the cross-sectional study (q = 0.033, linear regression). Conclusions AC concentrations in urine and blood were associated with red meat intake in both a highly controlled intervention study and in subjects of a cross-sectional study. Our data on the role of meat intake on this important pathway of fatty acid and energy metabolism may help understanding the role of red meat consumption in the etiology of some chronic diseases. This trial was registered at Clinicaltrials.gov as NCT03354130.
- Published
- 2020
43. Anthropometric and reproductive factors and risk of esophageal and gastric cancer by subtype and subsite: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
- Author
-
Sanikini, H., Sophiea, M., Rinaldi, S., Agudo, A., Duell, E.J., Weiderpass, E., Overvad, K., Tjønneland, A., Halkjær, J., Boutron-Ruault, M.-C., Carbonnel, F., Cervenka, I., Boeing, H., Kaaks, R., Kühn, T., Trichopoulou, A., Martimianaki, G., Karakatsani, A., Pala, V., Palli, D., Mattiello, A., Tumino, R., Sacerdote, C., Skeie, G., Rylander, C., Chirlaque López, M.-D., Sánchez, M.-J., Ardanaz, E., Regnér, S., Stocks, T., Bueno-de-Mesquita, B., Vermeulen, R.C.H., Aune, D., Tong, T.Y.N., Kliemann, N., Murphy, N., Chadeau-Hyam, M., Gunter, M.J., Cross, A.J., IRAS OH Epidemiology Chemical Agents, and dIRAS RA-2
- Subjects
reproductive ,obesity ,hormones ,esophageal ,cancer ,gastric - Abstract
Obesity has been associated with upper gastrointestinal cancers; however, there are limited prospective data on associations by subtype/subsite. Obesity can impact hormonal factors, which have been hypothesized to play a role in these cancers. We investigated anthropometric and reproductive factors in relation to esophageal and gastric cancer by subtype and subsite for 476,160 participants from the European Prospective Investigation into Cancer and Nutrition cohort. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox models. During a mean follow-up of 14 years, 220 esophageal adenocarcinomas (EA), 195 esophageal squamous cell carcinomas, 243 gastric cardia (GC) and 373 gastric noncardia (GNC) cancers were diagnosed. Body mass index (BMI) was associated with EA in men (BMI ≥30 vs. 18.5–25 kg/m2: HR = 1.94, 95% CI: 1.25–3.03) and women (HR = 2.66, 95% CI: 1.15–6.19); however, adjustment for waist-to-hip ratio (WHR) attenuated these associations. After mutual adjustment for BMI and HC, respectively, WHR and waist circumference (WC) were associated with EA in men (HR = 3.47, 95% CI: 1.99–6.06 for WHR >0.96 vs. 98 vs. 0.82 vs. 84 vs. 2 vs. 0) and age at first pregnancy and GNC (HR = 0.54, 95% CI: 0.32–0.91; >26 vs.
- Published
- 2020
44. Consumption of Fish and Long-chain n-3 Polyunsaturated Fatty Acids Is Associated With Reduced Risk of Colorectal Cancer in a Large European Cohort
- Author
-
Aglago, E.K. Huybrechts, I. Murphy, N. Casagrande, C. Nicolas, G. Pischon, T. Fedirko, V. Severi, G. Boutron-Ruault, M.-C. Fournier, A. Katzke, V. Kühn, T. Olsen, A. Tjønneland, A. Dahm, C.C. Overvad, K. Lasheras, C. Agudo, A. Sánchez, M.-J. Amiano, P. Huerta, J.M. Ardanaz, E. Perez-Cornago, A. Trichopoulou, A. Karakatsani, A. Martimianaki, G. Palli, D. Pala, V. Tumino, R. Naccarati, A. Panico, S. Bueno-de-Mesquita, B. May, A. Derksen, J.W.G. Hellstrand, S. Ohlsson, B. Wennberg, M. Van Guelpen, B. Skeie, G. Brustad, M. Weiderpass, E. Cross, A.J. Ward, H. Riboli, E. Norat, T. Chajes, V. Gunter, M.J.
- Abstract
Background & Aims: There is an unclear association between intake of fish and long-chain n-3 polyunsaturated fatty acids (n-3 LC-PUFAs) and colorectal cancer (CRC). We examined the association between fish consumption, dietary and circulating levels of n-3 LC-PUFAs, and ratio of n-6:n-3 LC-PUFA with CRC using data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Methods: Dietary intake of fish (total, fatty/oily, lean/white) and n-3 LC-PUFA were estimated by food frequency questionnaires given to 521,324 participants in the EPIC study; among these, 6291 individuals developed CRC (median follow up, 14.9 years). Levels of phospholipid LC-PUFA were measured by gas chromatography in plasma samples from a sub-group of 461 CRC cases and 461 matched individuals without CRC (controls). Multivariable Cox proportional hazards and conditional logistic regression models were used to calculate hazard ratios (HRs) and odds ratios (ORs), respectively, with 95% CIs. Results: Total intake of fish (HR for quintile 5 vs 1, 0.88; 95% CI, 0.80–0.96; Ptrend = .005), fatty fish (HR for quintile 5 vs 1, 0.90; 95% CI, 0.82–0.98; Ptrend = .009), and lean fish (HR for quintile 5 vs 1, 0.91; 95% CI, 0.83–1.00; Ptrend = .016) were inversely associated with CRC incidence. Intake of total n-3 LC-PUFA (HR for quintile 5 vs 1, 0.86; 95% CI, 0.78–0.95; Ptrend = .010) was also associated with reduced risk of CRC, whereas dietary ratio of n-6:n-3 LC-PUFA was associated with increased risk of CRC (HR for quintile 5 vs 1, 1.31; 95% CI, 1.18–1.45; Ptrend < .001). Plasma levels of phospholipid n-3 LC-PUFA was not associated with overall CRC risk, but an inverse trend was observed for proximal compared with distal colon cancer (Pheterogeneity = .026). Conclusions: In an analysis of dietary patterns of participants in the EPIC study, we found regular consumption of fish, at recommended levels, to be associated with a lower risk of CRC, possibly through exposure to n-3 LC-PUFA. Levels of n-3 LC-PUFA in plasma were not associated with CRC risk, but there may be differences in risk at different regions of the colon. © 2020 AGA Institute
- Published
- 2020
45. Healthy lifestyle and the risk of pancreatic cancer in the EPIC study
- Author
-
Naudin, S. Viallon, V. Hashim, D. Freisling, H. Jenab, M. Weiderpass, E. Perrier, F. McKenzie, F. Bueno-de-Mesquita, H.B. Olsen, A. Tjønneland, A. Dahm, C.C. Overvad, K. Mancini, F.R. Rebours, V. Boutron-Ruault, M.-C. Katzke, V. Kaaks, R. Bergmann, M. Boeing, H. Peppa, E. Karakatsani, A. Trichopoulou, A. Pala, V. Masala, G. Panico, S. Tumino, R. Sacerdote, C. May, A.M. van Gils, C.H. Rylander, C. Borch, K.B. Chirlaque López, M.D. Sánchez, M.-J. Ardanaz, E. Quirós, J.R. Amiano Exezarreta, P. Sund, M. Drake, I. Regnér, S. Travis, R.C. Wareham, N. Aune, D. Riboli, E. Gunter, M.J. Duell, E.J. Brennan, P. Ferrari, P.
- Abstract
Pancreatic cancer (PC) is a highly fatal cancer with currently limited opportunities for early detection and effective treatment. Modifiable factors may offer pathways for primary prevention. In this study, the association between the Healthy Lifestyle Index (HLI) and PC risk was examined. Within the European Prospective Investigation into Cancer and Nutrition cohort, 1113 incident PC (57% women) were diagnosed from 400,577 participants followed-up for 15 years (median). HLI scores combined smoking, alcohol intake, dietary exposure, physical activity and, in turn, overall and central adiposity using BMI (HLIBMI) and waist-to-hip ratio (WHR, HLIWHR), respectively. High values of HLI indicate adherence to healthy behaviors. Cox proportional hazard models with age as primary time variable were used to estimate PC hazard ratios (HR) and 95% confidence intervals (CI). Sensitivity analyses were performed by excluding, in turn, each factor from the HLI score. Population attributable fractions (PAF) were estimated assuming participants’ shift to healthier lifestyles. The HRs for a one-standard deviation increment of HLIBMI and HLIWHR were 0.84 (95% CI: 0.79, 0.89; ptrend = 4.3e−09) and 0.77 (0.72, 0.82; ptrend = 1.7e−15), respectively. Exclusions of smoking from HLIWHR resulted in HRs of 0.88 (0.82, 0.94; ptrend = 4.9e−04). The overall PAF estimate was 19% (95% CI: 11%, 26%), and 14% (6%, 21%) when smoking was removed from the score. Adherence to a healthy lifestyle was inversely associated with PC risk, beyond the beneficial role of smoking avoidance. Public health measures targeting compliance with healthy lifestyles may have an impact on PC incidence. © 2019, Springer Nature B.V.
- Published
- 2020
46. Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study
- Author
-
Kühn, T. Stepien, M. López-Nogueroles, M. Damms-Machado, A. Sookthai, D. Johnson, T. Roca, M. Hüsing, A. Maldonado, S.G. Cross, A.J. Murphy, N. Freisling, H. Rinaldi, S. Scalbert, A. Fedirko, V. Severi, G. Boutron-Ruault, M.-C. Mancini, F.R. Sowah, S.A. Boeing, H. Jakszyn, P. Sánchez, M.J. Merino, S. Colorado-Yohar, S. Barricarte, A. Khaw, K.T. Schmidt, J.A. Perez-Cornago, A. Trichopoulou, A. Karakatsani, A. Thriskos, P. Palli, D. Agnoli, C. Tumino, R. Sacerdote, C. Panico, S. Bueno-De-Mesquita, B. Van Gils, C.H. Heath, A.K. Gunter, M.J. Riboli, E. Lahoz, A. Jenab, M. Kaaks, R.
- Abstract
Background: Bile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans. Methods: Associations between prediagnostic plasma levels of 17 primary, secondary, and tertiary bile acid metabolites (conjugated and unconjugated) and colon cancer risk were evaluated in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Bile acid levels were quantified by tandem mass spectrometry in samples from 569 incident colon cancer cases and 569 matched controls. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) for colon cancer risk across quartiles of bile acid concentrations. Results: Positive associations were observed between colon cancer risk and plasma levels of seven conjugated bile acid metabolites: the primary bile acids glycocholic acid (ORquartile 4 vs quartile 1= 2.22, 95% confidence interval [CI] = 1.52 to 3.26), taurocholic acid (OR = 1.78, 95% CI = 1.23 to 2.58), glycochenodeoxycholic acid (OR = 1.68, 95% CI = 1.13 to 2.48), taurochenodeoxycholic acid (OR = 1.62, 95% CI = 1.11 to 2.36), and glycohyocholic acid (OR = 1.65, 95% CI = 1.13 to 2.40), and the secondary bile acids glycodeoxycholic acid (OR = 1.68, 95% CI = 1.12 to 2.54) and taurodeoxycholic acid (OR = 1.54, 95% CI = 1.02 to 2.31). By contrast, unconjugated bile acids and tertiary bile acids were not associated with risk. Conclusions: This prospective study showed that prediagnostic levels of certain conjugated primary and secondary bile acids were positively associated with risk of colon cancer. Our findings support experimental data to suggest that a high bile acid load is colon cancer promotive. © 2020 The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
- Published
- 2020
47. Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses
- Author
-
Seyed Khoei, N., Jenab, M., Murphy, N., Banbury, B.L., Carreras-Torres, R., Viallon, V., Kühn, T., Bueno-de-Mesquita, B., Aleksandrova, K., Cross, A.J., Weiderpass, E., Stepien, M., Bulmer, A., Tjønneland, A., Boutron-Ruault, M.C., Severi, G., Carbonnel, F., Katzke, V., Boeing, H., Bergmann, M.M., Trichopoulou, A., Karakatsani, A., Martimianaki, G., Palli, D., Tagliabue, G., Panico, S., Tumino, R., Sacerdote, C., Skeie, G., Merino, S., Bonet, C., Rodríguez-Barranco, M., Gil, L., Chirlaque, M.D., Ardanaz, E., Myte, R., Hultdin, J., Perez-Cornago, A., Aune, D., Tsilidis, K.K., Albanes, D., Baron, J.A., Berndt, S.I., Bézieau, S., Brenner, H., Campbell, P.T., Casey, G., Chang-Claude, J., Chanock, S.J., Cotterchio, M., Gallinger, S., Gruber, S.B., Haile, R.W., Hampe, J., Hoffmeister, M., Hopper, J.L., Hsu, L., Huyghe, J.R., Jenkins, M.A., Joshi, A.D., Kampman, E., Larsson, S.C., Le Marchand, L., Li, C.I., Li, L., Lindblom, A., Lindor, N.M., Martín, V., Moreno, V., Newcomb, P.A., Offit, K., Ogino, S., Parfrey, P.S., Pharoah, P.D.P., Rennert, G., Sakoda, L.C., Schafmayer, C., Schmit, S.L., Schoen, R.E., Slattery, M.L., Thibodeau, S.N., Ulrich, C.M., van Duijnhoven, F.J.B., Weigl, K., Weinstein, S.J., White, E., Wolk, A., Woods, M.O., Wu, A.H., Zhang, X., Ferrari, P., Anton, G., Peters, A., Peters, U., Gunter, M.J., Wagner, K.H., and Freisling, H.
- Subjects
Bilirubin ,Cancer ,Colorectal Cancer ,Anti-oxidants ,Mendelian Randomization Analysis - Abstract
Background Bilirubin, a byproduct of hemoglobin breakdown and purported anti-oxidant, is thought to be cancer preventive. We conducted complementary serological and Mendelian randomization (MR) analyses to investigate whether alterations in circulating levels of bilirubin are associated with risk of colorectal cancer (CRC). We decided a priori to perform analyses separately in men and women based on suggestive evidence that associations may differ by sex. Methods In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC), pre-diagnostic unconjugated bilirubin (UCB, the main component of total bilirubin) concentrations were measured by high-performance liquid chromatography in plasma samples of 1386 CRC cases and their individually matched controls. Additionally, 115 single-nucleotide polymorphisms (SNPs) robustly associated (P < 5 x 10(-8)) with circulating total bilirubin were instrumented in a 2-sample MR to test for a potential causal effect of bilirubin on CRC risk in 52,775 CRC cases and 45,940 matched controls in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), the Colon Cancer Family Registry (CCFR), and the Colorectal Transdisciplinary (CORECT) study. Results The associations between circulating UCB levels and CRC risk differed by sex (P-heterogeneity = 0.008). Among men, higher levels of UCB were positively associated with CRC risk (odds ratio [OR] = 1.19, 95% confidence interval [CI] = 1.04-1.36; per 1-SD increment of log-UCB). In women, an inverse association was observed (OR = 0.86 (0.76-0.97)). In the MR analysis of the mainUGT1A1SNP (rs6431625), genetically predicted higher levels of total bilirubin were associated with a 7% increase in CRC risk in men (OR = 1.07 (1.02-1.12);P = 0.006; per 1-SD increment of total bilirubin), while there was no association in women (OR = 1.01 (0.96-1.06);P = 0.73). Raised bilirubin levels, predicted by instrumental variables excluding rs6431625, were suggestive of an inverse association with CRC in men, but not in women. These differences by sex did not reach formal statistical significance (P-heterogeneity >= 0.2). Conclusions Additional insight into the relationship between circulating bilirubin and CRC is needed in order to conclude on a potential causal role of bilirubin in CRC development.
- Published
- 2020
48. Association between nutritional profiles of foods underlying Nutri-Score front-of-pack labels and mortality: EPIC cohort study in 10 European countries
- Author
-
Deschasaux, M. Huybrechts, I. Julia, C. Hercberg, S. Egnell, M. Srour, B. Kesse-Guyot, E. Latino-Martel, P. Biessy, C. Casagrande, C. Murphy, N. Jenab, M. Ward, H.A. Weiderpass, E. Overvad, K. Tjønneland, A. Rostgaard-Hansen, A.L. Boutron-Ruault, M.-C. Mancini, F.R. Mahamat-Saleh, Y. Kühn, T. Katzke, V. Bergmann, M.M. Schulze, M.B. Trichopoulou, A. Karakatsani, A. Peppa, E. Masala, G. Agnoli, C. De Magistris, M.S. Tumino, R. Sacerdote, C. Boer, J.M.A. Monique Verschuren, W.M. Van Der Schouw, Y.T. Skeie, G. Braaten, T. Luisa Redondo, M. Agudo, A. Petrova, D. Colorado-Yohar, S.M. Barricarte, A. Amiano, P. Sonestedt, E. Ericson, U. Otten, J. Sundström, B. Wareham, N.J. Forouhi, N.G. Vineis, P. Tsilidis, K.K. Knuppel, A. Papier, K. Ferrari, P. Riboli, E. Gunter, M.J. Touvier, M.
- Abstract
Objective To determine if the Food Standards Agency nutrient profiling system (FSAm-NPS), which grades the nutritional quality of food products and is used to derive the Nutri-Score front-of-packet label to guide consumers towards healthier food choices, is associated with mortality. Design Population based cohort study. Setting European Prospective Investigation into Cancer and Nutrition (EPIC) cohort from 23 centres in 10 European countries. Participants 521 324 adults; at recruitment, country specific and validated dietary questionnaires were used to assess their usual dietary intakes. A FSAm-NPS score was calculated for each food item per 100 g content of energy, sugars, saturated fatty acids, sodium, fibre, and protein, and of fruit, vegetables, legumes, and nuts. The FSAm-NPS dietary index was calculated for each participant as an energy weighted mean of the FSAm-NPS score of all foods consumed. The higher the score the lower the overall nutritional quality of the diet. Main outcome measure Associations between the FSAm-NPS dietary index score and mortality, assessed using multivariable adjusted Cox proportional hazards regression models. Results After exclusions, 501 594 adults (median follow-up 17.2 years, 8 162 730 person years) were included in the analyses. Those with a higher FSAm-NPS dietary index score (highest versus lowest fifth) showed an increased risk of all cause mortality (n=53 112 events from non-external causes; hazard ratio 1.07, 95% confidence interval 1.03 to 1.10, P
- Published
- 2020
49. Predicted basal metabolic rate and cancer risk in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Kliemann, N. Murphy, N. Viallon, V. Freisling, H. Tsilidis, K.K. Rinaldi, S. Mancini, F.R. Fagherazzi, G. Boutron-Ruault, M.-C. Boeing, H. Schulze, M.B. Masala, G. Krogh, V. Sacerdote, C. de Magistris, M.S. Bueno-de-Mesquita, B. Weiderpass, E. Kühn, T. Kaaks, R. Jakszyn, P. Redondo-Sánchez, D. Amiano, P. Chirlaque, M.-D. Gurrea, A.B. Ericson, U. Drake, I. Nøst, T.H. Aune, D. May, A.M. Tjønneland, A. Dahm, C.C. Overvad, K. Tumino, R. Quirós, J.R. Trichopoulou, A. Karakatsani, A. La Vecchia, C. Nilsson, L.M. Riboli, E. Huybrechts, I. Gunter, M.J.
- Abstract
Emerging evidence suggests that a metabolic profile associated with obesity may be a more relevant risk factor for some cancers than adiposity per se. Basal metabolic rate (BMR) is an indicator of overall body metabolism and may be a proxy for the impact of a specific metabolic profile on cancer risk. Therefore, we investigated the association of predicted BMR with incidence of 13 obesity-related cancers in the European Prospective Investigation into Cancer and Nutrition (EPIC). BMR at baseline was calculated using the WHO/FAO/UNU equations and the relationships between BMR and cancer risk were investigated using multivariable Cox proportional hazards regression models. A total of 141,295 men and 317,613 women, with a mean follow-up of 14 years were included in the analysis. Overall, higher BMR was associated with a greater risk for most cancers that have been linked with obesity. However, among normal weight participants, higher BMR was associated with elevated risks of esophageal adenocarcinoma (hazard ratio per 1-standard deviation change in BMR [HR1-SD]: 2.46; 95% CI 1.20; 5.03) and distal colon cancer (HR1-SD: 1.33; 95% CI 1.001; 1.77) among men and with proximal colon (HR1-SD: 1.16; 95% CI 1.01; 1.35), pancreatic (HR1-SD: 1.37; 95% CI 1.13; 1.66), thyroid (HR1-SD: 1.65; 95% CI 1.33; 2.05), postmenopausal breast (HR1-SD: 1.17; 95% CI 1.11; 1.22) and endometrial (HR1-SD: 1.20; 95% CI 1.03; 1.40) cancers in women. These results indicate that higher BMR may be an indicator of a metabolic phenotype associated with risk of certain cancer types, and may be a useful predictor of cancer risk independent of body fatness. © 2019 International Agency for Research on Cancer (IARC/WHO); licensed by UICC
- Published
- 2020
50. A nutrient-wide association study for risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition and the Netherlands Cohort Study
- Author
-
Papadimitriou, N. Muller, D. van den Brandt, P.A. Geybels, M. Patel, C.J. Gunter, M.J. Lopez, D.S. Key, T.J. Perez-Cornago, A. Ferrari, P. Vineis, P. Weiderpass, E. Boeing, H. Agudo, A. Sánchez, M.-J. Overvad, K. Kühn, T. Fortner, R.T. Palli, D. Drake, I. Bjartell, A. Santiuste, C. Bueno-de-Mesquita, B.H. Krogh, V. Tjønneland, A. Lauritzen, D.F. Gurrea, A.B. Quirós, J.R. Stattin, P. Trichopoulou, A. Martimianaki, G. Karakatsani, A. Thysell, E. Johansson, I. Ricceri, F. Tumino, R. Larrañaga, N. Khaw, K.T. Riboli, E. Tzoulaki, I. Tsilidis, K.K.
- Abstract
Purpose: The evidence from the literature regarding the association of dietary factors and risk of prostate cancer is inconclusive. Methods: A nutrient-wide association study was conducted to systematically and comprehensively evaluate the associations between 92 foods or nutrients and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cox proportional hazard regression models adjusted for total energy intake, smoking status, body mass index, physical activity, diabetes and education were used to estimate hazard ratios and 95% confidence intervals for standardized dietary intakes. As in genome-wide association studies, correction for multiple comparisons was applied using the false discovery rate (FDR ' 5%) method and suggested results were replicated in an independent cohort, the Netherlands Cohort Study (NLCS). Results: A total of 5916 and 3842 incident cases of prostate cancer were diagnosed during a mean follow-up of 14 and 20 years in EPIC and NLCS, respectively. None of the dietary factors was associated with the risk of total prostate cancer in EPIC (minimum FDR-corrected P, 0.37). Null associations were also observed by disease stage, grade and fatality, except for positive associations observed for intake of dry cakes/biscuits with low-grade and butter with aggressive prostate cancer, respectively, out of which the intake of dry cakes/biscuits was replicated in the NLCS. Conclusions: Our findings provide little support for an association for the majority of the 92 examined dietary factors and risk of prostate cancer. The association of dry cakes/biscuits with low-grade prostate cancer warrants further replication given the scarcity in the literature. © 2019, The Author(s).
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.